NZ614551B2 - 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace) - Google Patents
6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace) Download PDFInfo
- Publication number
- NZ614551B2 NZ614551B2 NZ614551A NZ61455112A NZ614551B2 NZ 614551 B2 NZ614551 B2 NZ 614551B2 NZ 614551 A NZ614551 A NZ 614551A NZ 61455112 A NZ61455112 A NZ 61455112A NZ 614551 B2 NZ614551 B2 NZ 614551B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- phenyl
- acid
- mmol
- vacuo
- Prior art date
Links
- 101700044176 BACE Proteins 0.000 title abstract description 19
- 230000002401 inhibitory effect Effects 0.000 title abstract description 14
- 239000003112 inhibitor Substances 0.000 title abstract description 8
- 101700051112 BACE1 Proteins 0.000 title abstract description 5
- IWEFEVCBSHDDLF-UHFFFAOYSA-N 6,7-dihydropyrazolo[1,5-a]pyrazin-4-amine Chemical class NC1=NCCN2N=CC=C12 IWEFEVCBSHDDLF-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 180
- -1 BACEl Proteins 0.000 claims abstract description 93
- 238000000034 method Methods 0.000 claims abstract description 64
- 206010001897 Alzheimer's disease Diseases 0.000 claims abstract description 42
- 206010012289 Dementia Diseases 0.000 claims abstract description 39
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims abstract description 19
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 206010057668 Cognitive disease Diseases 0.000 claims abstract description 11
- 206010061536 Parkinson's disease Diseases 0.000 claims abstract description 11
- 206010039966 Senile dementia Diseases 0.000 claims abstract description 11
- 206010067889 Dementia with Lewy body Diseases 0.000 claims abstract description 9
- 201000010374 Down syndrome Diseases 0.000 claims abstract description 9
- 201000002832 Lewy body dementia Diseases 0.000 claims abstract description 9
- 206010044688 Trisomy 21 Diseases 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 239000011780 sodium chloride Substances 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 22
- 125000005843 halogen group Chemical group 0.000 claims description 21
- 238000007792 addition Methods 0.000 claims description 15
- 239000012453 solvate Substances 0.000 claims description 14
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 229940035295 Ting Drugs 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000005412 pyrazyl group Chemical group 0.000 claims description 4
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000005495 pyridazyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 230000001225 therapeutic Effects 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 230000000069 prophylaxis Effects 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 160
- 102000004190 Enzymes Human genes 0.000 abstract description 9
- 108090000790 Enzymes Proteins 0.000 abstract description 9
- 102100015650 BACE1 Human genes 0.000 abstract description 6
- 108030001047 EC 3.4.23.46 Proteins 0.000 abstract description 2
- XUZNSOLCFRLBDV-FQEVSTJZSA-N C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]2(C)N=C(N)C3=C(F)C(C)=NN3C2)=C1 Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]2(C)N=C(N)C3=C(F)C(C)=NN3C2)=C1 XUZNSOLCFRLBDV-FQEVSTJZSA-N 0.000 abstract 2
- 239000000543 intermediate Substances 0.000 description 290
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 234
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 118
- 239000000243 solution Substances 0.000 description 94
- 239000002904 solvent Substances 0.000 description 94
- 238000002360 preparation method Methods 0.000 description 91
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 91
- 238000006243 chemical reaction Methods 0.000 description 83
- 239000000741 silica gel Substances 0.000 description 82
- 229910002027 silica gel Inorganic materials 0.000 description 82
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 74
- 238000003818 flash chromatography Methods 0.000 description 71
- 239000007787 solid Substances 0.000 description 68
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 60
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 37
- 239000012043 crude product Substances 0.000 description 36
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 36
- 239000012044 organic layer Substances 0.000 description 35
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 32
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 239000002253 acid Substances 0.000 description 27
- 239000012071 phase Substances 0.000 description 27
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 26
- 238000005160 1H NMR spectroscopy Methods 0.000 description 25
- 239000003921 oil Substances 0.000 description 25
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 24
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 23
- 235000019341 magnesium sulphate Nutrition 0.000 description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 239000002585 base Substances 0.000 description 17
- 229910002092 carbon dioxide Inorganic materials 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 238000004166 bioassay Methods 0.000 description 15
- 238000010438 heat treatment Methods 0.000 description 15
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 15
- 125000003373 pyrazinyl group Chemical group 0.000 description 15
- 239000012047 saturated solution Substances 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 14
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 13
- 239000012442 inert solvent Substances 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000000875 corresponding Effects 0.000 description 12
- 229910000029 sodium carbonate Inorganic materials 0.000 description 12
- 210000004027 cells Anatomy 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- 235000019270 ammonium chloride Nutrition 0.000 description 10
- 239000003054 catalyst Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 125000001207 fluorophenyl group Chemical group 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 102100017796 APP Human genes 0.000 description 9
- 108060000460 APP Proteins 0.000 description 9
- 239000001569 carbon dioxide Substances 0.000 description 9
- 239000000969 carrier Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- PJYFXNZOOMGPIL-UHFFFAOYSA-N 2-methylmorpholin-4-ium;chloride Chemical compound Cl.CC1CNCCO1 PJYFXNZOOMGPIL-UHFFFAOYSA-N 0.000 description 8
- AVVLVCYNVBXDSH-UHFFFAOYSA-N 4-[(4,6-dimethoxy-1,3,5-triazin-2-yl)methyl]morpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC(C[NH+]2CCOCC2)=N1 AVVLVCYNVBXDSH-UHFFFAOYSA-N 0.000 description 8
- CSJLBAMHHLJAAS-UHFFFAOYSA-N Diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 8
- 229940088598 Enzyme Drugs 0.000 description 8
- 102000004965 antibodies Human genes 0.000 description 8
- 108090001123 antibodies Proteins 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000006722 reduction reaction Methods 0.000 description 8
- 238000004007 reversed phase HPLC Methods 0.000 description 8
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 8
- 239000003643 water by type Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 108010037444 diisopropylglutathione ester Proteins 0.000 description 7
- 230000005284 excitation Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000001603 reducing Effects 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- 210000004556 Brain Anatomy 0.000 description 6
- 210000001736 Capillaries Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 5
- 102100004109 HEY1 Human genes 0.000 description 5
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000001413 cellular Effects 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 235000017550 sodium carbonate Nutrition 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N Lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M Sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 235000011089 carbon dioxide Nutrition 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 238000000132 electrospray ionisation Methods 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000003287 optical Effects 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 150000003556 thioamides Chemical class 0.000 description 4
- JYKZCYLZWZCQFP-UHFFFAOYSA-N 3,5-dichloropyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC=C(Cl)C=C1Cl JYKZCYLZWZCQFP-UHFFFAOYSA-N 0.000 description 3
- 229940024606 Amino Acids Drugs 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001808 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940093499 ethyl acetate Drugs 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- FFLYUXVZEPLMCL-UHFFFAOYSA-N ethylchloranuidyl formate Chemical compound CC[Cl-]OC=O FFLYUXVZEPLMCL-UHFFFAOYSA-N 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000006263 metalation reaction Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 238000005055 short column chromatography Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000001187 sodium carbonate Substances 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- DZHSAHHDTRWUTF-SIQRNXPUSA-N β-amyloid polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 3
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- UNHYHSXKOVCSSK-UHFFFAOYSA-N 2-(7-methoxy-2-oxochromen-3-yl)acetic acid Chemical compound C1=C(CC(O)=O)C(=O)OC2=CC(OC)=CC=C21 UNHYHSXKOVCSSK-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N Adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 2
- 101700067048 CDC13 Proteins 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 208000005145 Cerebral Amyloid Angiopathy Diseases 0.000 description 2
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 229940012356 Eye Drops Drugs 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N Gentisic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N Hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N Hippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- CFHGBZLNZZVTAY-UHFFFAOYSA-N Lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N Manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 210000001331 Nose Anatomy 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N Palmitic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229940072417 Peroxidase Drugs 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 108090000437 Peroxidases Proteins 0.000 description 2
- 210000002381 Plasma Anatomy 0.000 description 2
- 231100000614 Poison Toxicity 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- YBCAZPLXEGKKFM-UHFFFAOYSA-K Ruthenium(III) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M Sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M Sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N Sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N Tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000003542 behavioural Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 230000002939 deleterious Effects 0.000 description 2
- MBWXLICVQZUJOW-UHFFFAOYSA-N diethyl 1H-pyrazole-3,5-dicarboxylate Chemical compound CCOC(=O)C=1C=C(C(=O)OCC)NN=1 MBWXLICVQZUJOW-UHFFFAOYSA-N 0.000 description 2
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical compound C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 description 2
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000001965 increased Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminum hydride Chemical compound [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 2
- 238000011068 load Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 230000003340 mental Effects 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 101700014033 nhr-5 Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- GMQOZFVOGGIFIX-UHFFFAOYSA-N oxathiazolidine Chemical compound C1COSN1 GMQOZFVOGGIFIX-UHFFFAOYSA-N 0.000 description 2
- MBACRDZWRXWNMY-UHFFFAOYSA-N oxathiazolidine 2,2-dioxide Chemical compound O=S1(=O)NCCO1 MBACRDZWRXWNMY-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000002797 proteolythic Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000007280 thionation reaction Methods 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N (+)-tartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KWMLJOLKUYYJFJ-AIECOIEWSA-N (2R,3R,4R,5S,6R)-2,3,4,5,6,7-hexahydroxyheptanoic acid Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-AIECOIEWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N (±)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- JYUXDXWXTPSAEL-UHFFFAOYSA-N 1,4-dioxane;oxolane Chemical compound C1CCOC1.C1COCCO1 JYUXDXWXTPSAEL-UHFFFAOYSA-N 0.000 description 1
- JYAQYXOVOHJRCS-UHFFFAOYSA-N 1-(3-bromophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(Br)=C1 JYAQYXOVOHJRCS-UHFFFAOYSA-N 0.000 description 1
- WYTBQTMYNBKLHE-UHFFFAOYSA-N 1-(5-amino-2-fluorophenyl)ethanone Chemical compound CC(=O)C1=CC(N)=CC=C1F WYTBQTMYNBKLHE-UHFFFAOYSA-N 0.000 description 1
- IUAGBSGAPCSVAE-UHFFFAOYSA-N 1-(difluoromethyl)pyrazole-3-carboxylic acid Chemical compound OC(=O)C=1C=CN(C(F)F)N=1 IUAGBSGAPCSVAE-UHFFFAOYSA-N 0.000 description 1
- ZVXTUAKXYXKULZ-UHFFFAOYSA-N 1H-pyrazole-3,5-dicarboxamide Chemical compound NC(=O)C=1C=C(C(N)=O)NN=1 ZVXTUAKXYXKULZ-UHFFFAOYSA-N 0.000 description 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- CDMVTUNTTIPYGM-UHFFFAOYSA-N 2-amino-2-(3-nitrophenyl)propanenitrile Chemical compound N#CC(N)(C)C1=CC=CC([N+]([O-])=O)=C1 CDMVTUNTTIPYGM-UHFFFAOYSA-N 0.000 description 1
- UPDHOZIVRZUNPZ-UHFFFAOYSA-N 2-methyl-1,3-thiazolidine 1-oxide Chemical compound CC1NCCS1=O UPDHOZIVRZUNPZ-UHFFFAOYSA-N 0.000 description 1
- XTMUXJBJCMRWPG-UHFFFAOYSA-N 3-chloropyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC=CC=C1Cl XTMUXJBJCMRWPG-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-Aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 229940046932 4-aminosalicylic acid Drugs 0.000 description 1
- WVGCPEDBFHEHEZ-UHFFFAOYSA-N 4-bromo-1H-pyrazole Chemical compound BrC=1C=NNC=1 WVGCPEDBFHEHEZ-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- PYXNITNKYBLBMW-UHFFFAOYSA-N 5-(trifluoromethyl)-1H-pyrazole Chemical compound FC(F)(F)C1=CC=NN1 PYXNITNKYBLBMW-UHFFFAOYSA-N 0.000 description 1
- HRLVPHGCEGTVLK-UHFFFAOYSA-N 5-cyanopyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(C#N)C=N1 HRLVPHGCEGTVLK-UHFFFAOYSA-N 0.000 description 1
- 229940005529 ANTIPSYCHOTICS Drugs 0.000 description 1
- 229940005530 ANXIOLYTICS Drugs 0.000 description 1
- OXTNCQMOKLOUAM-UHFFFAOYSA-N Acetonedicarboxylic acid Chemical compound OC(=O)CC(=O)CC(O)=O OXTNCQMOKLOUAM-UHFFFAOYSA-N 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 229940019746 Antifibrinolytic amino acids Drugs 0.000 description 1
- 206010002855 Anxiety Diseases 0.000 description 1
- 206010057666 Anxiety disease Diseases 0.000 description 1
- XTEGVFVZDVNBPF-UHFFFAOYSA-N Armstrong's acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 1
- HXWUJJADFMXNKA-UHFFFAOYSA-N Asparaginyl-Leucine Chemical compound CC(C)CC(C(O)=O)NC(=O)C(N)CC(N)=O HXWUJJADFMXNKA-UHFFFAOYSA-N 0.000 description 1
- 108091005540 Aspartic proteases Proteins 0.000 description 1
- 102000035336 Aspartic proteases Human genes 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N BINAP Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N Benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N Benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 230000035579 Brain Levels Effects 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L Calcium hydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N Camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N Carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 210000001638 Cerebellum Anatomy 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N Cesium Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N Cyclamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229960002887 Deanol Drugs 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N Dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N Diethylethanolamine Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- BDUPRNVPXOHWIL-UHFFFAOYSA-N Dimethyl sulfite Chemical compound COS(=O)OC BDUPRNVPXOHWIL-UHFFFAOYSA-N 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N Ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N Isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N Lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- XBZOQGHZGQLEQO-IUCAKERBSA-N Lys-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN XBZOQGHZGQLEQO-IUCAKERBSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N Mucic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N N,N'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- OKSCQOCCIXWPET-UHFFFAOYSA-N NC(CC)(O)C1=CC=CC(=C1)[N+](=O)[O-] Chemical compound NC(CC)(O)C1=CC=CC(=C1)[N+](=O)[O-] OKSCQOCCIXWPET-UHFFFAOYSA-N 0.000 description 1
- STKVQLBDUSMSLD-UHFFFAOYSA-N NC1=NN2C(C=NCC2)=C1 Chemical compound NC1=NN2C(C=NCC2)=C1 STKVQLBDUSMSLD-UHFFFAOYSA-N 0.000 description 1
- 206010053643 Neurodegenerative disease Diseases 0.000 description 1
- 210000002682 Neurofibrillary Tangles Anatomy 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 229960005010 Orotic Acid Drugs 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N Orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L Palladium(II) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- CYQAYERJWZKYML-UHFFFAOYSA-N Phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
- 229940018489 Pronto Drugs 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N Pyroglutamic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 210000001202 Rhombencephalon Anatomy 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 229940083608 Sodium Hydroxide Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N TFA trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940033123 Tannic Acid Drugs 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N Tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N Tert-Butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M Tetra-n-butylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N Thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L Tin(II) chloride Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J Tin(IV) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical class [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N Trifluoromethanesulfonic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- LEIMLDGFXIOXMT-UHFFFAOYSA-N Trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229960004418 Trolamine Drugs 0.000 description 1
- 229940035504 Tromethamine Drugs 0.000 description 1
- 241000822135 Ula Species 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N Undecylenic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L Zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- HMVLJYFGTNSCHZ-JTQLQIEISA-N [(2R)-2-(3-bromophenyl)-1-hydroxypropan-2-yl]carbamic acid Chemical compound OC(=O)N[C@](CO)(C)C1=CC=CC(Br)=C1 HMVLJYFGTNSCHZ-JTQLQIEISA-N 0.000 description 1
- ROZSPJBPUVWBHW-UHFFFAOYSA-N [Ru]=O Chemical compound [Ru]=O ROZSPJBPUVWBHW-UHFFFAOYSA-N 0.000 description 1
- WXIONIWNXBAHRU-UHFFFAOYSA-N [dimethylamino(triazolo[4,5-b]pyridin-3-yloxy)methylidene]-dimethylazanium Chemical compound C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 WXIONIWNXBAHRU-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- LAYDWGNLLRXNPH-UHFFFAOYSA-N acetic acid;dicyclohexylazanide;palladium(2+) Chemical compound [Pd+2].CC(O)=O.CC(O)=O.C1CCCCC1[N-]C1CCCCC1.C1CCCCC1[N-]C1CCCCC1 LAYDWGNLLRXNPH-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000561 anti-psychotic Effects 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000000949 anxiolytic Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- WIRUZQNBHNAMAB-UHFFFAOYSA-N benzene;cyclohexane Chemical compound C1CCCCC1.C1=CC=CC=C1 WIRUZQNBHNAMAB-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229940095643 calcium hydroxide Drugs 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbamate Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001149 cognitive Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- PMSVVUSIPKHUMT-UHFFFAOYSA-N cyanopyrazine Chemical compound N#CC1=CN=CC=N1 PMSVVUSIPKHUMT-UHFFFAOYSA-N 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 230000001809 detectable Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- NUCWDCRUEIUKPN-UHFFFAOYSA-J ethane-1,2-diamine;palladium(2+);phosphonato phosphate Chemical compound [Pd+2].[Pd+2].NCCN.NCCN.[O-]P([O-])(=O)OP([O-])([O-])=O NUCWDCRUEIUKPN-UHFFFAOYSA-J 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- MSPOSRHJXMILNK-UHFFFAOYSA-N ethyl 1H-pyrazole-5-carboxylate Chemical compound CCOC(=O)C1=CC=NN1 MSPOSRHJXMILNK-UHFFFAOYSA-N 0.000 description 1
- SNZZJCBTYCCHNG-UHFFFAOYSA-N ethyl 3-nitro-1H-pyrazole-5-carboxylate Chemical compound CCOC(=O)C1=CC([N+]([O-])=O)=NN1 SNZZJCBTYCCHNG-UHFFFAOYSA-N 0.000 description 1
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(II) oxide Inorganic materials [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 230000000926 neurological Effects 0.000 description 1
- 230000002887 neurotoxic Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative Effects 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching Effects 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 238000002165 resonance energy transfer Methods 0.000 description 1
- 229910001925 ruthenium oxide Inorganic materials 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000004544 spot-on Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- HKAOFPWOXIVYAN-UHFFFAOYSA-N sulfamoylazanide Chemical compound NS([NH-])(=O)=O HKAOFPWOXIVYAN-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 229940029612 triethanolamine Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Disclosed herein are 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-yl-amine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACEl, Asp2, or memapsin2. Also disclosed are pharmaceutical compositions comprising such compounds, processes for preparing such compounds and compositions, and the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid. In one embodiment the compound is (R)-5-methoxy-pyrazine-2-carboxylic acid [3-(4-amino-3-fluoro-2, 6-dimethyl-6,7-dihydro-pyrazolo[1, 5-a]pyrazin-6-yl)-4-fluoro-phenyl]amide. pounds and compositions, and the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid. In one embodiment the compound is (R)-5-methoxy-pyrazine-2-carboxylic acid [3-(4-amino-3-fluoro-2, 6-dimethyl-6,7-dihydro-pyrazolo[1, 5-a]pyrazin-6-yl)-4-fluoro-phenyl]amide.
Description
,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZINYLAMINE DERIVATIVES
USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
FIELD OF THE INVENTION
The present ion s to novel 6,7-dihydro-pyrazolo[l,5-a]pyrazinyl-
amine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid
cleaving enzyme, BACE, BACEl, Asp2, or memapsin2. The invention is also directed
to pharmaceutical compositions comprising such compounds, to processes for
preparing such compounds and compositions, and to the use of such compounds and
compositions for the prevention and treatment of disorders in which beta-secretase is
involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility,
ia, dementia with Lewy bodies, Down's syndrome, dementia associated with
stroke, dementia associated with Parkinson's disease or dementia associated with beta-
amyloid.
BACKGROUND OF THE INVENTION
Alzheimer's Disease (AD) is a neurodegenerative disease ated with aging.
AD patients suffer from cognition deficits and memory loss as well as behavioral
ms such as anXiety. Over 90% of those afflicted with AD have a sporadic form of
the er while less than 10% of the cases are familial or hereditary. In the United
, about 1 in 10 people at age 65 have AD while at age 85, 1 out of every two
individuals are affected with AD. The average life expectancy from the initial diagnosis
is 7-10 years, and AD patients require extensive care either in an assisted living facility
which is very costly or by family members. With the increasing number of elderly in
the population, AD is a g medical concern. Currently ble therapies for AD
merely treat the ms of the disease and include acetylcholinesterase inhibitors to
improve cognitive properties as well as anXiolytics and antipsychotics to control the
behavioral ms associated with this ailment.
The hallmark pathological features in the brain of AD ts are
3O neurofibrillary tangles which are ted by hyperphosphorylation of tau protein and
amyloid plaques which form by aggregation of beta-amyloid l-42 (Abeta l-42)
peptide. Abeta l-42 forms oligomers and then fibrils, and ultimately amyloid plaques.
The oligomers and fibrils are believed to be ally neurotoxic and may cause most
of the neurological damage associated with AD. Agents that prevent the formation of
Abeta l-42 have the potential to be disease-modifying agents for the treatment of AD.
Abeta l-42 is generated from the amyloid precursor protein (APP), comprised of 770
amino acids. The N-terminus of Abeta 1-42 is d by beta-secretase (BACE), and
then gamma-secretase cleaves the inal end. In addition to Abeta 1-42, gamma-
secretase also liberates Abeta 1-40 which is the predominant cleavage product as well
as Abeta 1-38 and Abeta 1-43. These Abeta forms can also aggregate to form oligomers
and fibrils. Thus, inhibitors of BACE would be expected to prevent the formation of
Abeta 1-42 as well as Abeta 1-40, Abeta 1-38 and Abeta 1-43 and would be potential
therapeutic agents in the treatment of AD.
SUMMARY OF THE ION
The present ion is directed to a compound of Formula (I)
R \ N
\N RX4
HZN L
\ \Ar
X1 2¢X3
‘X
or a tautomer or a stereoisomeric form thereof, wherein
R1 and R2 are independently selected from the group consisting of hydrogen, halo,
cyano, C1-3alkyl, mono- and polyhalo-C1.3alkyl or C3_6cycloalkyl,
R3 is selected from the group consisting of en, C1_3alkyl,
C3-6cycloalkyl, mono- and polyhalo-C1-3alkyl, homoaryl and heteroaryl,
X1, X2, X3, X4 are independently C(R4) or N, provided that no more than two thereof
represent N, each R4 is selected from the group ting of hydrogen, halo, C1_3alkyl,
mono- and polyhalo-C1-3alkyl, cyano, C1-3alkyloxy, mono- and polyhalo-C1_3alkyloxy,
L is a bond or -N(R5)CO-, wherein R5 is hydrogen or C1_3alkyl,
Ar is homoaryl or heteroaryl,
wherein homoaryl is phenyl or phenyl tuted with one, two or three substituents
selected from the group consisting of halo, cyano, C1-3alkyl, C1_3alkyloxy, mono- and
polyhalo-C1_3alkyl, mono- and polyhalo-C1_3alkyloxy,
heteroaryl is selected from the group consisting of pyridyl, pyrimidyl, pyrazyl,
pyridazyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl,
azolyl, oxazolyl, and oxadiazolyl, each optionally substituted with one, two or
three substituents selected from the group consisting of halo, cyano, C1_3alkyl,
C1_3alkyloxy, mono- and lo-C1_3alkyl, mono- and polyhalo-C1_3alkyloxy, or
an addition salt or a solvate thereof
Illustrative of the invention is a pharmaceutical composition comprising a
pharmaceutically acceptable carrier and any of the compounds described above. An
illustration of the invention is a ceutical composition made by mixing any of the
compounds described above and a pharmaceutically acceptable carrier. Illustrating the
invention is a process for making a pharmaceutical composition comprising mixing any
of the compounds described above and a pharmaceutically able carrier.
Exemplifying the invention are methods of ng a disorder mediated by the
beta-secretase enzyme, comprising stering to a subject in need thereof a
therapeutically effective amount of any of the compounds or pharmaceutical
compositions described above.
Further exemplifying the invention are methods of inhibiting the beta-secretase
enzyme, comprising administering to a subject in need f a therapeutically
effective amount of any of the compounds or ceutical compositions described
above.
An example of the invention is a method of treating a disorder selected from the
group consisting of Alzheimer's disease, mild cognitive impairment, senility, dementia,
dementia with Lewy bodies, Down's me, dementia associated with ,
dementia ated with Parkinson's disease and dementia associated with beta-
amyloid, preferably Alzheimer's disease, comprising stering to a subject in need
thereof, a therapeutically effective amount of any of the compounds or ceutical
compositions described above.
Another example of the invention is any of the compounds described above for
use in treating: (a) Alzheimer's Disease, (b) mild cognitive impairment, (c) senility, (d)
dementia, (e) dementia with Lewy , (f) Down's me, (g) dementia
associated with stroke, (h) dementia associated with Parkinson's disease and (i)
dementia associated with beta-amyloid, in a subject in need thereof
DETAILED DESCRIPTION OF THE INVENTION
The present ion is directed to compounds of formula (I) as defined
hereinbefore and pharmaceutically acceptable salts and solvates thereof The
3O compounds of formula (I) are inhibitors of the beta-secretase enzyme (also known as
beta-site cleaving enzyme, BACE, BACEl or in 2), and are useful in
, Asp2
the treatment of Alzheimer's disease, mild cognitive impairment, senility, dementia,
dementia associated with stroke, dementia with Lewy bodies, Down's syndrome,
dementia associated with Parkinson's disease and dementia associated with beta-
amyloid, preferably Alzheimer's e, mild cognitive impairment or ia, more
preferably Alzheimer's disease.
In an embodiment of the t invention, R1 and R2 are independently
selected from hydrogen and C1_3alkyl,
X1, X2, X3, X4 are independently C(R4) wherein each R4 is selected from en and
halo,
L is a bond or -N(R5)CO-, wherein R5 is hydrogen;
Ar is homoaryl or heteroaryl,
wherein homoaryl is phenyl or phenyl substituted with one or two substituents ed
from the group consisting of halo, cyano, kyl, C1.3alkyloxy, and
polyhalo-C1_3alkyloxy,
heteroaryl is selected from the group consisting of pyridyl, pyrimidyl, and pyrazyl, each
optionally substituted with one or two substituents selected from the group consisting
of halo, cyano, C1-3alkyl, C1-3alkyloxy, and polyhalo-C1_3alkyloxy, or
an addition salt or a solvate thereof.
In another embodiment of the present invention, R1 and R2 are hydrogen,
X1, X2, X3, X4 are CH,
L is a bond or -N(R5)CO-, wherein R5 is hydrogen,
Ar is homoaryl or heteroaryl,
n homoaryl is phenyl substituted with chloro,
heteroaryl is selected from the group consisting of pyridyl and pyrimidyl, each
2O optionally substituted with one or two substituents selected from the group ting
of chloro, fluoro, cyano, methyl, and methoxy, or
an addition salt or a solvate thereof.
In another embodiment, the carbon atom tuted with R3 has the R-
configuration.
DEFINITIONS
“Halo” shall denote fluoro, chloro and bromo, lkyl” shall denote a straight
or branched saturated alkyl group having 1, 2 or 3 carbon atoms, e. g. methyl, ethyl,
l-propyl and 2-propyl, “C1_3alkyloxy” shall denote an ether radical n C1-3alkyl is
as defined before, “mono- and polyhaloC1.3alkyl” shall denote C1-3alkyl as defined
3O before, tuted with l, 2 3 or where possible with more halo atoms as defined
before, “mono- and polyhaloC1-3alkyloxy” shall denote an ether radical wherein mono-
and polyhaloC1-3alkyl is as defined before, ycloalkyl” shall denote cyclopropyl,
cyclobutyl, cyclopentyl and cyclohexyl, “C3-6cycloalkanediyl” shall denote a bivalent
radical such as cyclopropanediyl, cyclobutanediyl, cyclopentanediyl and
cyclohexanediyl.
The term "subject" as used , refers to an animal, preferably a mammal,
most preferably a human, who is or has been the object of treatment, observation or
experiment.
The term "therapeutically effective amount" as used herein, means that amount
of active compound or pharmaceutical agent that elicits the biological or medicinal
se in a tissue , animal or human that is being sought by a researcher,
veterinarian, medical doctor or other clinician, which es alleviation of the
symptoms of the disease or disorder being treated.
As used herein, the term sition" is intended to encompass a product
sing the specified ingredients in the specified s, as well as any product
which results, ly or indirectly, from combinations of the specified ingredients in
the specified amounts.
Hereinbefore and hereinafter, the term “compound of a (1)” is meant to include
the on salts, the solvates and the stereoisomers thereof.
The terms “stereoisomers” or “stereochemically isomeric forms” hereinbefore
or hereinafter are used interchangeably.
The invention includes all stereoisomers of the compound of Formula (I) either as a
pure stereoisomer or as a mixture of two or more stereoisomers.
Enantiomers are stereoisomers that are non-superimposable mirror images of
each other. A 1:1 mixture of a pair of enantiomers is a te or racemic mixture.
Diastereomers (or diastereoisomers) are stereoisomers that are not enantiomers,
i.e. they are not related as mirror images. If a compound ns a double bond, the
substituents may be in the E or the Z configuration. If a compound contains a
disubstituted cycloalkyl group, the substituents may be in the cis or trans configuration.
Therefore, the invention includes enantiomers, diastereomers, racemates, E isomers,
Z isomers, cis isomers, trans isomers and mixtures thereof
The absolute configuration is specified ing to the Cahn-Ingold-Prelog
system. The configuration at an asymmetric atom is specified by either R or S.
Resolved nds whose absolute configuration is not known can be designated by
(+) or (-) depending on the direction in which they rotate plane polarized light.
When a specific stereoisomer is identified, this means that said isomer is
substantially free, i.e. associated with less than 50%, preferably less than 20%, more
preferably less than 10%, even more preferably less than 5%, in particular less than 2%
and most preferably less than 1%, of the other isomers. Thus, when a compound of
formula (I) is for instance specified as (R), this means that the compound is
substantially free of the (S) isomer, when a compound of formula (I) is for instance
specified as E, this means that the compound is substantially free of the Z isomer, when
a compound of formula (I) is for instance specified as cis, this means that the
compound is substantially free of the trans isomer.
The compounds ula (I) co-exist in a dynamic brium with the
tautomers of Formula (I-l).
R2 R2
\ ~l\{
R1 \ N R1 \ N
R3 ‘—
X L X L
H2N Nj<f \ HN ”kw3R Y W
1 3 1 3
X\X2-.X X\x2“X
(I) (H)
rmore, some of the crystalline forms for the nds of the present
invention may exist as polymorphs and as such are intended to be included in the
present invention. In addition, some of the compounds of the t invention may
form solvates with water (i.e., es) or common organic solvents, and such solvates
are also intended to be encompassed within the scope of this invention.
For use in medicine, the salts of the compounds of this invention refer to non-
toxic "pharmaceutically able salts". Other salts may, however, be useful in the
preparation of compounds according to this invention or of their pharmaceutically
acceptable salts. Suitable pharmaceutically acceptable salts of the compounds include
acid addition salts which may, for example, be formed by mixing a solution of the
compound with a solution of a pharmaceutically acceptable acid such as hydrochloric
acid, sulfuric acid, fumaric acid, maleic acid, ic acid, acetic acid, benzoic acid,
citric acid, ic acid, carbonic acid or phosphoric acid. Furthermore, where the
compounds of the invention carry an acidic moiety, suitable pharmaceutically
acceptable salts thereof may include alkali metal salts, e.g., sodium or potassium salts,
alkaline earth metal salts, e.g., calcium or magnesium salts, and salts formed with
suitable organic ligands, e.g., quaternary ammonium salts.
Representative acids which may be used in the preparation of pharmaceutically
acceptable salts include, but are not limited to, the following: acetic acid,
2,2-dichloroacetic acid, ed amino acids, adipic acid, alginic acid, ascorbic acid,
rtic acid, benzenesulfonic acid, benzoic acid, 4- idobenzoic acid,
(+)-camphoric acid, camphorsulfonic acid, capric acid, caproic acid, caprylic acid,
cinnamic acid, citric acid, cyclamic acid, ethane-1,2-disulfonic acid, ethanesulfonic
acid, 2-hydroxy-ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic
acid, glucoheptonic acid, D-gluconic acid, D-glucoronic acid, L-glutamic acid, beta-
oxo-glutaric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid,
(+)-L-lactic acid, (::)-DL-lactic acid, lactobionic acid, maleic acid, (-)—L-malic acid,
malonic acid, (::)-DL-mandelic acid, methanesulfonic acid, naphthalenesulfonic
acid, naphthalene-1,5- disulfonic acid, l-hydroxynaphthoic acid, nic acid,
nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric
acid, L- pyroglutamic acid, salicylic acid, 4-amino-salicylic acid, c acid, c
acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid,
p-toluenesulfonic acid, trifluoromethylsulfonic acid, and undecylenic acid.
Representative bases which may be used in the ation of pharmaceutically
acceptable salts include, but are not limited to, the following: ammonia, L-arginine,
benethamine, benzathine, calcium hydroxide, choline, dimethylethanolamine,
diethanolamine, diethylamine, 2-(diethylamino)-ethanol, ethanolamine, ethylenediamine
, N—methyl-glucamine, hydrabamine, lH-imidazole, L-lysine, magnesium
ide, 4-(2-hydroxyethyl)-morpholine, piperazine, potassium hydroxide,
l-(2-hydroxyethyl)-pyrrolidine, secondary amine, sodium hydroxide, triethanolamine,
tromethamine and zinc hydroxide.
The chemical names of the compounds of the present invention were generated
according to the nomenclature rules agreed upon by the Chemical Abstracts Service.
Some of the nds according to formula (I) may also exist in their tautomeric
form. Such forms although not explicitly indicated in the above formula are intended to
be ed within the scope of the present invention.
A. Preparation of the final compounds
Experimental procedure 1
The final nds according to Formula (I), can be prepared by ng an
intermediate compound of Formula (II) with an appropriate source of a such as,
for e, ammonium chloride or aqueous ammonia, according to reaction scheme
(1), a reaction that is performed in a suitable reaction-inert solvent, such as, for
example, water or methanol, under thermal conditions such as, for example, heating the
reaction e at 60 to 90 °C, for example for 4 to 100 hours. In reaction scheme (1),
all variables are defined as in Formula (1).
R1 \ N R1 \ N
R3 "ammonia source" R3
s N X4 L\ HZN \N X4 L\
H Ar
I Y I
1 3
X \XZX
(ll)
Reaction Scheme 1
WO 17027
Experimental procedure 2
The final nds according to Formula (I-a) wherein L is -N(R5)CO-, can
be prepared by reacting an intermediate compound of a (III-a) with an
intermediate of Formula (IV) according to reaction scheme (2), a reaction that is
performed in a suitable reaction-inert solvent, such as, for example, N,N—dimethyl-
formamide, in the presence of a suitable base, such as, for example, K3PO4, a copper
catalyst such as, for example, CuI and a diamine such as for example (lR,2R)-(-)-l,2-
diaminocyclohexane, under thermal conditions such as, for example, g the
reaction mixture at 180 °C, for example for 135 min under microwave irradiation. In
reaction scheme (2), all variables are defined as in Formula (I) and W is halo.
R2 R2
‘N H —l\{
R1 \ N R5/NTAr R1 \ N
(N) O
\ 1:536 \ 1:536
N w N E5
HZN Ar HZN
1| \\(3 \\|/3
X xx x1 xx \[Or
(Ill-a) \xz (l-a) \XZ
Reaction Scheme 2
Experimental procedure 3
Additionally, the final compounds according to Formula (I-a), can be prepared
by reacting an intermediate compound of a ) with an intermediate of
Formula (V) according to reaction scheme (3), a reaction that is performed in a suitable
reaction-inert t, such as, for example, dichloromethane or methanol, optionally in
the presence of a suitable base, such as, for example, N,N—diisopropylethylamine, in the
presence of a condensation agent such as for example O-(7-azabenzotriazol-l-yl)-
N,N,N’,N’-tetramethyluronium hexafiuorophosphate or 4-(4,6-dimethoxy-1,3,5-triazin-
2-yl)methylmorpholinium chloride ], under thermal conditions such as, for e,
heating the reaction mixture at 25 °C, for example for 2 hours. In on scheme (3),
all variables are defined as in Formula (I).
—N —N
\ HO Ar \
\ N \[f R1 \ N
(V) o '3
\ R34
YNHR HZN N X\
1' N\n/Ar
X\ 22X 0
(IIIb) ”X (I-a) X
Reaction Scheme 3
Experimental procedure 4
Additionally, the final compounds according to Formula (I-a), can be ed
by reacting an intermediate compound of Formula ) with an intermediate of
Formula (VI) according to reaction scheme (4), a reaction that is performed in a
suitable reaction-inert solvent, such as, for e, dichloromethane, in the presence
of a suitable base, such as, for example, pyridine, under thermal conditions such as, for
example, heating the on mixture at 25 °C, for example for 2 hours. In reaction
scheme (4), all les are defined as in Formula (I) and Y is halo
j?\ \
(Vl)
NHR5 \n/Ar
(lll-b) \Zx' (l-a) 15(sz
Reaction Scheme 4
Experimental procedure 5
The final compounds according to a (I-b) wherein L is a bond, can be
prepared by reacting an intermediate compound of Formula (III-a) with an intermediate
of Formula (VII) ing to reaction scheme (5), a reaction that is performed in a
suitable reaction-inert solvent, such as, for example, mixtures of inert solvents such as,
2O for example, l,4-dioxane/ethanol, in the presence of a suitable base, such as, for
example, K2CO3, a Pd-complex catalyst such as, for e, tetrakis
(triphenylphosphine)palladium (0) under thermal conditions such as, for example,
heating the reaction mixture at 80 °C, for example for 20 hours or for example, heating
the reaction mixture at 150 °C, for 10 min to 30 min under microwave irradiation. In
reaction scheme (5), all variables are defined as in Formula (I) and W is halo. R6 and R7
may be hydrogen or alkyl, or may be taken er to form for example a bivalent
radical Of formula —CH2CH2-, 2CH2-, Of-C(CH3)2C(CH3)2-.
_ 10 _
R2 R2
—N ,O-R“ —N
R1 \ N Ar—B\O’R7 R1 \ N
\ 4 (V ) \ 4
H N N X W Ar
2 \\|/3 H N N X
1| 1| Y3
X '.X X :X
(Ill-a) \xz (l-b) \XZ
Reaction Scheme 5
Experimental procedure 6
The final compounds ing to a (I-c) wherein R1 is hydrogen, can be
prepared from the corresponding final compounds of Formula (I-d) wherein R1 is
selected from the group consisting of chlorine, bromine and iodine, following art-
known reduction procedures according to reaction scheme (6). For e, said
reduction may be carried out by stirring the reactants under a hydrogen atmosphere and
in the presence of an appropriate catalyst such as, for example, palladium-on-charcoal,
platinum-on-charcoal, Raney-nickel and the like catalysts. Suitable solvents are, for
example, water, alkanols, e. g. methanol, ethanol and the like, esters, e. g. ethyl acetate
and the like. In order to enhance the rate of said ion reaction it may be
advantageous to elevate the temperature and/or the pressure of the reaction mixture.
Undesired further enation of certain functional groups in the reactants and the
reaction products may be prevented by the on of a catalyst poison such as, for
e, thiophene and the like, to the reaction mixture. In reaction scheme (6), all
variables are defined as in Formula (I).
R2 R2
‘N. ~N\
R1 \ N \ N
"reduction" R3
\ 3:534 —> \ 4
H2N N X L\ H2N N X L\
1| \\(3 Ar
1| \\(3 Ar
X\sz X\XZX
(I-d) (l-c)
W
A number of intermediates and starting materials in the foregoing preparations
are known nds which may be prepared ing to art-known methodologies
of preparing said or similar compounds and some intermediates are new. A number of
such preparation methods will be described hereinafter in more detail.
B. Preparation of the intermediate compounds
Experimental procedure 7
The intermediates according to a (II) can be prepared by reacting an
intermediate compound of Formula (VIII) with a suitable sulphur donating reagent for
the synthesis of thioamides such as, for example, phosphorous pentasulflde or 2,4-bis-
(4-methoxyphenyl)—l,3-dithia-2,4-diphosphetane 2,4-disulf1de [Lawesson’s reagent]
according to reaction scheme (7), a reaction that is performed in a reaction inert
t, such as for example, tetrahydrofuran or toluene, in the presence of a suitable
base such as, for example, pyridine, under thermal conditions such as, for example,
heating the reaction mixture at 100 °C, for example for 5 hours. In reaction scheme (7),
all variables are defined as in Formula (I).
R2 R2
—N ~N
R1 \ N R1 \ N
"th10nat10n". .
R3 R3
O M X4 L X4 L\ 8
I \\(3 \Ar M Ar
X1\ Z—X X1\ 22X3
(VIII) X (H) X
Reaction Scheme 7
mental ure 8
The intermediates according to a (VIII-a) wherein L is a bond, can be
ed by reacting an intermediate nd of Formula (IX-a) with an intermediate
of Formula (VII) according to reaction scheme (8), a on that is performed in a
suitable mixture of inert solvents such as, for example, l,4-dioxane/water, in the
presence of a le base, such as, for example, aqueous Na2C03, a Pd-complex
catalyst such as, for example, tetrakis(triphenylphosphine)palladium (0) under thermal
conditions such as, for example, heating the reaction mixture at 80 °C, for example for
hours or for example, heating the reaction mixture at 150 °C, for example for 15 to
min under microwave irradiation. In reaction scheme (8), all variables are defined as
in Formula (I) and W is halo. R6 and R7 may be hydrogen or alkyl, or may be taken
together to form for example a bivalent radical of formula
2-, -CH2CH2CH2-, or -C(CH3)2C(CH3)2-.
WO 17027
R2 R2
—N ,O-R“ —N
R1 \ N Ar—B\ ’R7 R1 \ N
Mk; 0
(VII)
0 W —> o Ar
H 1' \\(3 HNE;1' Y3
X\ 29X X 2X
(IX-a) X (VIII-a) x
Reaction Scheme 8
mental procedure 9
The ediates according to Formula (III-b) can be prepared from the
corresponding intermediate compounds of Formula (III-a) following own
Buchwald-Hartwig type coupling procedures according to reaction scheme (9). Said
coupling may be conducted by treatment of intermediate nds of Formula (III-a)
with an intermediate of Formula (X) in a suitable reaction-inert solvent, such as, for
example, ethanol or mixtures of inert solvents such as, l,2-dimethoxyethane/water/
ethanol, in the presence of a suitable base, such as, for example, aqueous K3PO4 or
, a plex catalyst such as, for example, [1,1’-bis(diphenylphosphino)
ferrocene]-dichloropalladium(II) or trans-bis(dicyclohexylamine) palladium diacetate
[DAPCy] under thermal conditions such as, for example, g the on mixture at
80 0C, for example for 20 hours or for example, heating the reaction mixture at 130 °C,
for example for 10 min under microwave irradiation. In reaction scheme (9), all
variables are defined as in Formula (I) and W is halo. R5 is en or C1_3alkyl.
Alternatively, when R5 is en, intermediates of Formula (III-b) can be obtained as
well following a two-step synthesis. First, a Buchwald-Hartwig type coupling can be
2O performed, under the conditions known to the person skilled in the art, between
intermediate (III-a) and a stable imine such as benzophenone imine. In the second step,
intermediate (III-b) can be obtained as a primary amine by treating the coupled product,
dissolved in a suitable solvent, such as isopropanol, with an acid, such as for example
hydrochloric acid, under thermal conditions such as, for example, heating the reaction
mixture at 25 0C, for example for 2 hours.
R2 R2
‘N HZNR5 ‘N
R1 \ N R1 \ N
HN \Nji/Ri“ w \Njifi“ NHR5
2 H2N
X\ 22X X\ 21X
(Ill-a) X (Ill-b) X
Reaction Scheme 9
Experimental procedure 10
Additionally, the intermediates according to Formula (III-b) wherein R5 is
hydrogen can be prepared from the corresponding intermediates of Formula )
following art-known nitro-to-amino reduction procedures according to on scheme
(10). For example, said reduction may conveniently be conducted in presence of an
appropriate reducing agent such as tin chloride, zinc or iron, in a suitable inert t
such as ethanol or mixtures ethanol/acetic acid or methanol/ammonium chloride
aqueous solution, under suitable on conditions, such as at a convenient
temperature, lly ranging between 70 °C and 110 °C, for a period of time to ensure
the completion of the reaction. The person skilled in the art would appreciate that in the
case of R1 and/or R2 in intermediate (III-c) being a halogen selected from the group of
chlorine, bromine and iodine, and undesired in the final compound, under the above
described conditions also an oxidative addition-protonation process may occur, to
afford ediate (III-b), where R1 and/or R2 is hydrogen. Alternatively, said
reduction may be carried out by stirring the reactants under a hydrogen atmosphere and
in the presence of an appropriate catalyst such as, for example, palladium-on-charcoal,
platinum-on-charcoal, Raney-nickel and the like catalysts. Suitable solvents are, for
example, water, alkanols, e. g. methanol, ethanol and the like, esters, e. g. ethyl acetate
and the like. In order to enhance the rate of said reduction reaction it may be
advantageous to elevate the temperature and/or the pressure of the on mixture.
red r hydrogenation of certain filnctional groups in the nts and the
reaction products may be prevented by the on of a catalyst poison such as, for
e, thiophene and the like, to the reaction mixture. In reaction scheme (10), all
variablesare defined as in Formula (I).
a a"nitrotoaminoreduction"
”X x2
(III-c) (|||-b)
Reaction Scheme 10
Experimental procedure 11
The compounds ofFormula (III-a) and (III-c) can generally be prepared
ing the reaction steps shown in the reaction schemes (1 l) and (12) below.
(XIII-a) R = Alkyl (XIII-c) R = H
R1 \ N
PGHN IXYNOZ
X1\ X3
Reaction Scheme 11
A: Thioamide-to-amidine conversion
B: Amide-to-thioamide conversion (thionation)
C: Cyclization
D: Removing any N—protecting groups
E: Metalation
The amidine derivatives in the above reaction scheme (1 1) may be conveniently
prepared from the corresponding thioamide derivatives following art-known thioamide-
to-amidine conversion ures (reaction step A). Said conversion may conveniently
be conducted by treatment of the said thioamides with an ammonia source such as, for
example, ammonium chloride or aqueous ammonia, in a suitable reaction-inert solvent
such as, for e, water or ol and the like, under thermal conditions such as,
for example, heating the reaction e at 60 to 90 0C, for example for 6 to 100
hours.
The thioamide derivatives in the above reaction scheme (1 1) can be ed
from amide derivatives ing art-known tion procedures (reaction step B).
Said conversion may conveniently be conducted by treatment of the said amides with a
thionation agent such as, for example, orous pentasulf1de or 2,4-bis-(4-methoxy-
phenyl)-l,3-dithia-2,4-diphosphetane 2,4-disulf1de [Lawesson’s reagent], under neat
conditions or in a reaction inert solvent such as, for example, tetrahydrofuran or 1,4-
dioxane and the like, optionally in the presence of a suitable base like pyridine under
thermal conditions such as, for e, heating the reaction mixture at 50 to 100 °C,
for example for 24 hours.
The amide derivatives of Formula (IX-a) and (IX-c) in the above reaction
scheme (1 1) can be prepared from the corresponding intermediate nds of
Formula (XII-a) and (XII-c) following art-known cyclization procedures (reaction step
C). Said cyclization may conveniently be conducted by treatment of ediate
compounds ofFormula ) and ) with a suitable base, such as potassium
acetate, in a suitable reaction solvent, such as for example ethanol and the like, at 70 °C
to 100 °C, for a period of time to ensure the completion of the reaction.
The intermediates of Formula (IX-a), wherein R2 is hydrogen, can be prepared
from an intermediate of Formula (IX-a-l), n R2 is nitro, by reduction of the nitro
3O to the amino group, followed by a diazotization-deamination reaction.
The intermediates of Formula (IX-a), wherein R2 is difluoromethyl, can be
prepared from an intermediate of Formula (IX-a-2), wherein R2 is alkoxycarbonyl, by
conversion of the ester group into an aldehyde by one of the several methods known to
the person skilled in the art, followed by reaction of the aldehyde group with DAST.
The intermediate compounds of Formula (XII-a) and (XII-c) in the above
reaction scheme (1 1) can be prepared from the ponding intermediate compounds
_ 16 _
of Formula (XIII-a) and (XIII-c) by removal of the ting group being carried out
according to processes known to the person skilled in the art ion step D).
The intermediate compound of Formula (XIII-c) in the above reaction scheme
(1 1) can be prepared from the corresponding intermediate nds of Formula
(XIV-c) following art-known metalation ures (reaction step E). Said metalation
may conveniently be conducted by treatment of intermediate compounds of Formula
(XIV-c) with a suitable base, such as lithium diisopropylamide, and a suitable
electrophile such as dry ice or ethyl chloroformate, in a suitable reaction solvent, such
as for example tetrahydrofuran, at -80 °C to 0 °C, for a period of time to ensure the
completion of the reaction.
R2 R2
/ R1 \ N
R020 4
PGHN
1| XYNOZ
X X3
\X22 (XIII-a)X2R= Alkyl (XIV-c)
R2 R2
R \‘Nile
F R1/6N\ NH F
ROZC (XV-a) (XV-c)
R=Alky|
d’SW936:?
w O: NO
\Y, (57W(936:?\Y 2
1' 1'
1x 3X
Z \Xz \XZ
(XVI-a) (XVI-c)
'G G
CW4 CW4 . X w . X No2
O/IS\N I Y O/IS\N I Y
\1 X1 2X3 \
1 X1 2x3)
Z \Xz Z \XZ
(XVII-a) (XVII-c)
H H
HO HO
R3 4 R3 4
X w X NO2
HI}! I Y HN Y
21 X1\ 23X3 21 X1: 22X3
X X
(XVIII-a) (XVIII-c)
Reaction Scheme 12
F: tion
G: Oxathiazolidine oxidation
H: Oxathiazolidine formation
The intermediates ing to Formula (XIII-a) and (XIV-c) in the above
reaction scheme (12) can be prepared from the corresponding intermediate compounds
of Formula (XVI-a) and ), wherein Z1 is a protecting group of amines such as,
for example, the lerl—butoxycarbonyl group, following art-known alkylation procedures
(reaction step F). Said alkylation may conveniently be ted by treatment of
(XV-a) and (XV-c) respectively with the corresponding intermediate compounds of
a (XVI-a) and (XVI-c) with a suitable base such as, for example, sodium
carbonate or cesium ate, in a suitable inert solvent such as, for example,
N,N—dimethyl formamide or dimethoxysulfoxide, at low ature such as, for
example, 0 °C for 30 min and then at a moderately high temperature such as, for
e, 100 °C for 24 hours to 100 hours or for example, heating the reaction mixture
at 130 °C, for example for 30 min to 45 min under microwave irradiation.
The intermediates according to Formula (XVI-a) and (XVI-c) in the above
reaction scheme (12) can be prepared by reacting the intermediate nds of
Formula a) and (XVII-c) following art-known ion procedures (reaction
step G). Said oxidation may conveniently be conducted by treatment of the
corresponding intermediate compounds of Formula (XVII-a) and c) with an
oxidant agent such as, for e, sodium periodate in a suitable inert solvent such as,
for example, acetonitrile/water, in the presence of ruthenium (III) chloride at a
moderately high ature such as, for example, 25 °C, for example for 2 hours.
The intermediates according to Formula (XVII-a) and (XVII-c) in the above
reaction scheme (12) can be prepared by reacting the intermediate compounds of
Formula (XVIII-a) and (XVIII-c) following art-known sulfamidate formation
2O procedures (reaction step H). Said transformation may conveniently be conducted by
treatment of the corresponding intermediate compounds of Formula (XVIII-a) and
(XVIII-c) with thionyl chloride in the presence of a base such as, for example,
ne, in a suitable reaction-inert solvent, such as, for example, acetonitrile, at low
temperature such as, for example, -40 °C, for example for 30 min and then at a
moderately high temperature such as, for example, 25 °C, for example for 24 to 72
hours.
The intermediates compounds of Formula -a) and (XVIII-c), wherein Z1
is a protecting group of amines such as, for example, the ZerZ-butoxycarbonyl group,
can lly be prepared following art-known Strecker type procedures described in
3O literature.
PHARMACOLOGY
The compounds of the present invention and the pharmaceutically acceptable
compositions f inhibit BACE and therefore may be useful in the treatment or
tion of Alzheimer’s Disease (AD), mild cognitive impairment (MCI), senility,
dementia, dementia with Lewy bodies, cerebral amyloid angiopathy, multi-infarct
2012/053455
ia, Down’s syndrome, dementia associated with Parkinson’s disease and
dementia associated with beta-amyloid.
The invention relates to a nd according to the general Formula (I), a
stereoisomeric form thereof or a pharmaceutically acceptable acid or base addition salt
or a solvate thereof, for use as a medicament.
The invention also relates to a compound ing to the general Formula (I),
a stereoisomeric form thereof or a the pharmaceutically acceptable acid or base
addition salt or a solvate thereof, for use in the treatment or prevention of diseases or
conditions selected from the group consisting of AD, MCI, senility, dementia, dementia
with Lewy bodies, cerebral amyloid angiopathy, multi-infarct dementia, Down's
syndrome, ia associated with Parkinson's disease and dementia associated with
beta-amyloid.
The invention also relates to the use of a compound according to the general
Formula (I), a stereoisomeric form thereof or a pharmaceutically acceptable acid or
base addition salt or a solvate thereof, for the manufacture of a medicament for the
treatment or prevention of any one of the e conditions mentioned before.
In view of the utility of the nd of Formula (I), there is ed a
method of treating warm-blooded animals, including humans, suffering from or a
method of preventing warm-blooded animals, including humans, to suffer from any one
of the diseases mentioned hereinbefore.
Said methods comprise the stration, i.e. the systemic or l
administration, preferably oral administration, of an ive amount of a compound of
Formula (I), a stereoisomeric form thereof, a pharmaceutically acceptable addition salt
or solvate thereof, to a warm-blooded animal, including a human.
A method of treatment may also include administering the active ingredient on
a regimen of between one and four intakes per day. In these methods of treatment the
compounds according to the invention are preferably formulated prior to
stration. As described herein below, suitable pharmaceutical formulations are
prepared by known procedures using well known and readily available ingredients.
3O The compounds of the present invention, that can be suitable to treat or prevent
Alzheimer's disease or the symptoms thereof, may be administered alone or in
ation with one or more additional therapeutic agents. Combination therapy
includes administration of a single pharmaceutical dosage formulation which contains a
compound of Formula (I) and one or more additional therapeutic agents, as well as
stration of the nd of Formula (I) and each additional therapeutic agents
in its own separate pharmaceutical dosage formulation. For example, a compound of
Formula (I) and a therapeutic agent may be administered to the t together in a
single oral dosage composition such as a tablet or capsule, or each agent may be
administered in separate oral dosage formulations.
PHARMACEUTICAL COMPOSITIONS
The present invention also provides compositions for preventing or treating
diseases in which inhibition of beta-secretase is beneficial, such as mer's disease
(AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies,
Down's syndrome, dementia ated with stroke, dementia associated with
Parkinson's disease and dementia ated with beta-amyloid. Said compositions
comprising a therapeutically effective amount of a compound according to formula (I)
and a pharmaceutically acceptable carrier or diluent.
While it is possible for the active ingredient to be administered alone, it is
preferable to present it as a pharmaceutical composition. Accordingly, the present
invention further provides a pharmaceutical composition comprising a nd
according to the present invention, together with a pharmaceutically acceptable carrier
or diluent. The carrier or diluent must be “acceptable” in the sense of being compatible
with the other ingredients of the composition and not deleterious to the recipients
The pharmaceutical compositions of this invention may be prepared by any
methods well known in the art of pharmacy. A therapeutically effective amount of the
particular compound, in base form or on salt form, as the active ingredient is
combined in intimate admixture with a pharmaceutically able carrier, which may
take a wide variety of forms depending on the form of preparation d for
administration. These pharmaceutical compositions are desirably in unitary dosage
form suitable, ably, for systemic administration such as oral, aneous or
parenteral stration, or topical administration such as via tion, a nose spray,
eye drops or via a cream, gel, shampoo or the like. For example, in preparing the
compositions in oral dosage form, any of the usual pharmaceutical media may be
employed, such as, for e, water, glycols, oils, alcohols and the like in the case of
oral liquid ations such as sions, syrups, elixirs and solutions: or solid
3O carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and
the like in the case of powders, pills, capsules and tablets. Because of their ease in
administration, tablets and capsules represent the most advantageous oral dosage unit
form, in which case solid pharmaceutical carriers are obviously employed. For
parenteral compositions, the carrier will y comprise sterile water, at least in large
part, though other ingredients, for example, to aid solubility, may be included.
Injectable solutions, for example, may be prepared in which the carrier comprises
saline solution, glucose solution or a mixture of saline and glucose solution. Injectable
suspensions may also be prepared in which case riate liquid carriers, suspending
agents and the like may be employed. In the compositions suitable for percutaneous
administration, the carrier optionally ses a penetration enhancing agent and/or a
suitable wettable agent, optionally combined with suitable additives of any nature in
minor proportions, which additives do not cause any significant deleterious effects on
the skin. Said additives may facilitate the administration to the skin and/or may be
helpful for preparing the desired itions. These compositions may be
administered in various ways, e.g., as a transdermal patch, as a spot-on or as an
ointment.
It is ally advantageous to formulate the aforementioned pharmaceutical
compositions in dosage unit form for ease of administration and mity of dosage.
Dosage unit form as used in the ication and claims herein refers to ally
discrete units suitable as unitary dosages, each unit containing a predetermined ty
of active ient calculated to produce the desired therapeutic effect in association
with the required pharmaceutical carrier. Examples of such dosage unit forms are
tablets (including scored or coated tablets), capsules, pills, powder packets, wafers,
injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and
segregated multiples thereof
The exact dosage and frequency of administration depends on the particular
compound of formula (I) used, the particular condition being treated, the severity of the
condition being treated, the age, weight, sex, extent of disorder and general physical
condition of the particular patient as well as other tion the individual may be
taking, as is well known to those skilled in the art. Furthermore, it is evident that said
effective daily amount may be lowered or increased depending on the response of the
treated subject and/or depending on the tion of the ian prescribing the
compounds of the instant invention.
Depending on the mode of administration, the pharmaceutical composition will
comprise from 0.05 to 99% by weight, ably from 0.1 to 70% by weight, more
preferably from 0.1 to 50% by weight of the active ingredient, and, from 1 to 99.95%
by weight, preferably from 30 to 99.9% by weight, more preferably from 50 to 99.9%
by weight of a ceutically acceptable r, all percentages being based on the
total weight of the composition.
The present compounds can be used for systemic stration such as oral,
percutaneous or parenteral administration, or topical administration such as via
inhalation, a nose spray, eye drops or via a cream, gel, shampoo or the like. The
compounds are preferably orally administered. The exact dosage and frequency of
administration depends on the particular nd according to formula (I) used, the
particular condition being treated, the severity of the condition being treated, the age,
weight, sex, extent of disorder and general physical condition of the ular patient
as well as other medication the individual may be taking, as is well known to those
skilled in the art. rmore, it is t that said effective daily amount may be
lowered or sed ing on the response of the treated subject and/or depending
on the evaluation of the physician prescribing the compounds of the instant invention.
The amount of a compound of Formula (I) that can be combined with a carrier
material to produce a single dosage form will vary depending upon the disease treated,
the mammalian species, and the ular mode of administration. However, as a
general guide, suitable unit doses for the compounds of the present invention can, for
example, preferably contain between 0.1 mg to about 1000 mg of the active compound.
A preferred unit dose is between 1 mg to about 500 mg. A more preferred unit dose is
between 1 mg to about 300mg. Even more preferred unit dose is between 1 mg to about
100 mg. Such unit doses can be administered more than once a day, for example, 2, 3,
4, 5 or 6 times a day, but preferably 1 or 2 times per day, so that the total dosage for a
70 kg adult is in the range of 0.001 to about 15 mg per kg weight of subject per
administration. A preferred dosage is 0.01 to about 1.5 mg per kg weight of subject per
administration, and such y can extend for a number of weeks or months, and in
some cases, years. It will be understood, however, that the specific dose level for any
particular t will depend on a variety of factors including the activity of the
specific compound employed, the age, body weight, general health, sex and diet of the
dual being treated, the time and route of administration, the rate of excretion,
other drugs that have previously been administered, and the severity of the particular
disease undergoing therapy, as is well understood by those of skill in the area.
It can be necessary to use dosages outside these ranges in some cases as will be
apparent to those skilled in the art. Further, it is noted that the clinician or treating
physician will know how and when to start, upt, adjust, or terminate therapy in
conjunction with individual t response.
The following examples are intended to illustrate but not to limit the scope of
the present invention.
Experimental Part
Hereinafter, the term “AcOH” means acetic acid, “HCl” means hloric
acid, “AcOEt” means ethylacetate, “DCM” means dichloromethane, “DIPE” means
diisopropylether, “DMF” means N,N—dimethylformamide, “C02” means carbon
dioxide, “DMSO” means ylsulfoxide, “Eth” means diethylether, “Et3N” means
triethylamine, “EtOH” means ethanol, “iPrOH” means isopropanol, “iPrNHf‘ means
isopropylamine, “MeCN” means acetonitrile, “MeOH” means methanol, “NaOH”
means sodium ide, ” means ammonium chloride, “NH3” means
ammonia, “NaHCOg” means sodium bicarbonate, “NaHSO4” means sodium
hydrogenosulfate, “N212CO3” means sodium carbonate, “NaZSO4” means sodium
sulphate, “H2804” means sulphuric acid, “MgSO4” means magnesium sulphate, “CuI”
means copper iodide, “TFA” means trifuoromethansulfonic acid, “R1102” means
ruthenium oxide, “DAST” means diethylaminosulfur trifluoride, “DBU” means
l,8-diazabicyclo[5.4.0]undecene, “N2” means nitrogen, “C02” means carbon
dioxide, “aq.” means aqueous, “min” means minutes, “mp.” means melting point,
“rac” means racemic, “Rt” means retention times, “THF” means tetrahydrofuran,
“SFC” means supercritical fluid chromatography.
Microwave assisted reactions were performed in a single-mode reactor:
M Optimizer microwave reactor (Personal Chemistry A.B., currently Biotage).
Hydrogenation reactions were performed in a continuous flow hydrogenator
H-CUBE® from ThalesNano Nanotechnology Inc.
Thin layer chromatography (TLC) was carried out on silica gel 60 F254 plates
) using t grade solvents. Open column chromatography was performed on
silica gel, particle size 60 A, mesh = 23 0-400 (Merck) under standard techniques. Flash
column chromatography was performed using ready-to-connect cartridges from Merck,
on irregular silica gel, particle size 15-40 um (normal layer disposable flash s)
on an SPOT or LAFLASH system from Armen Instrument.
Optical rotations were ed on a Perkin-Elmer 341 polarimeter with a
sodium lamp and reported as follows: [oc]° (7», c g/ 100ml, solvent, T°C).
Flow reactions were performed in a commercially ble Vapourtec R2+R4
modular device.
For key intermediates, as well as some final compounds, the absolute
ration of chiral centers (indicated as R and/or 5) were established via
comparison with samples of known configuration, or the use of ical techniques
3O le for the determination of te configuration, such as VCD (vibrational
cicular dichroism) or X—ray crystallography. When the absolute ration at a
chiral center is unknown, it is arbitrarily designated R*.
A. Preparation of the intermediates
Example Al
Preparation of intermediate A1: racamino(3-bromo-phenyl)-propionitrile
Trimethylsilylcyanide (20 g, 200 mmol) was added to a stirred solution of 3-bromoacetophenone
(20 g, 100 mmol) and NH4Cl (11 g, 200 mmol) in NH3/Me0H (400 mL).
The mixture was stirred at room temperature for 4 days. The solvent was evaporated in
vacuo and the residue was taken up in AcOEt (100 mL). The solid was d off and
the filtrate was evaporated in vacuo to yield intermediate A1 (20 g, 86% yield), that
was used in the next step without further purification.
Example A2
Preparation of intermediate A2: racamino(3 -bromo-phenyl)-propionic acid
methyl ester
\\ O/
BoxH2N
ediate A1 (20 g, 88.9 mmol) was dissolved in HCl/MeOH (500 mL). The
mixture was refluxed for 4 days. After cooling to room temperature, AcOEt (100 mL)
and H20 (100 mL) were added and the mixture was extracted with AcOEt (2 x 100
mL). The combined aqueous layers were basified with an NH3 solution to pH = 8 and
extracted with AcOEt (5 x 100 mL). The combined organic layers were dried (Na2S04),
filtered and the solvents evaporated in vacuo to yield intermediate A2 (10.6 g, 46%
yield) as an oil. LCMS: 258 [M+H]+; R: 3.77 min (method 7).
The ing intermediate was prepared according to the synthetic procedures
bed in examples Al - A2:
Example A3
Preparation of intermediate A3: racamino(3-nitro-phenyl)-propionic acid methyl
ester
0 /
[\lll+ 2 O
From amino(3 -nitro-phenyl)-propionitrile. Flash column chromatography
(silica gel; AcOEt/petroleum ether) to yield intermediate 3 (63%). LCMS: 225
[M+H]+; R: 0.98 min (method 9).
_ 25 _
Example A4
Preparation of intermediate A4: racamino(3 -bromo-phenyl)-propanol
Lithium aluminium hydride (1 M in THF; 22 mL, 22 mmol) was added dropwise to a
stirred solution of intermediate A2 (7.5 g, 29.1 mmol) in THF (200 mL) at -15 °C. The
mixture was left g up slowly to 0 °C during 1 hour. More THF (150 mL) was
added and a saturated solution ofNaZSO4 was added se until no more hydrogen
was formed. ous NaZSO4 was added and left stirring overnight at room
temperature. The mixture was filtered over diatomaceous earth, washed with THF and
the solvent evaporated in vacuo. The crude product was purified by flash column
chromatography (silica gel; 7 M solution of1\H3 in MeOH/DCM). The desired
ons were collected and the solvents evaporated in vacuo to yield intermediate A4
(5.70 g, 85% yield) as an oil. LCMS: 230 [M--H]+; R: 0.69 min (method 1).
Example A5
Preparation of intermediate A5: amino(3-nitro-phenyl)-propanol
9- H2N
Sodium dride (16.3 g, 429.4 mmol) was added nwise to a stirred solution
of intermediate A3 (48.3 g, 214.7 mmol) in MeOH (500 mL). The mixture was stirred
at room temperature for 10 hours. The solvent was evaporated in vacuo. The residue
was basified with a saturated aqueous solution ofNaHC03 to pH = 9 and extracted with
AcOEt (3 x 200 mL). The organic layers were dried (NaZSO4), filtered and the solvents
evaporated in vacuo to yield intermediate A5 (30.26 g, 72% yield). LCMS: 197
[M+H]+; R: 3.16 min (method 8); mp. 238.7-241.6 °C (WRS-2A).
Example A6
Preparation of intermediate A6: (R)amino(3 -bromo-phenyl)-propanol
A sample of intermediate A4 (15.4 g) was separated into the corresponding
enantiomers by preparative SFC on lpak® Daicel AD x 250 mm). Mobile phase
(C02, MeOH with 0.2% leNHz) to yield ediate A6 (7.21 g, 40% yield). LCMS:
230 [M+H]+; R: 0.71 min (method 1); OLD: -14.9 ° (589 nm, c 0.2946 w/v%, MeOH,
0C).
Example A7
Preparation of intermediate A7: (R)-[1-(3-bromo-phenyl)hydroxymethyl-ethyl]-
carbamic acid lerl butyl ester
B ©>H§JEOA<
Di-lerl—butyldicarbonate (19.8 g, 90.7 mmol) was added portionwise to a stirred
solution of ediate A6 (11.6 g, 50.4 mmol) in a mixture of saturated solution of
NaHC03 (100 mL) and THF (100 mL) at 0 °C. The mixture was stirred at 0 °C for 10
min and at room temperature for 15 hours. The mixture was cooled in an ice/HZO bath
and acidified with stirring to pH = 1-2 with NaHSO4. The c layer was ted
and the aq. layer was further ted with AcOEt. The combined organic layers were
separated, dried (MgSO4), filtered and the solvents evaporated in vacuo. The crude
product was purified by short column chromatography (silica gel; AcOEt/DCM). The
desired fractions were collected and concentrated in vacuo to yield intermediate A7
(16.47 g, 99% yield) as a colorless oil that solidified upon standing. LCMS: 330
[M+H]+; R: 2.58 min d 1).
e A8
Preparation of intermediate A8: (R)-[3-(Zerl-butyloxycarbonyl)(3 -bromo-phenyl)
methyl-[1,1,3]oxathiazolidineoxide
, S\ N Br
(DI/k
O O
A solution of intermediate A7 (14.3 g, 43.3 mmol) in dry MeCN (80 mL) was added
dropwise to a stirred solution of thionyl chloride (7.9 mL, 108.3 mmol) in dry MeCN
(226 mL) cooled to -40 °C and under a N2 atmosphere. The reaction e was stirred
for 30 min at -40 °C before pyridine (17.4 mL, 216.5 mmol) was added. The reaction
was allowed to warm to room temperature and stirred for 64 hours. The solvents were
evaporated in vacuo. The residue was treated with EtzO. The solids were filtered and
the filtrate concentrated in vacuo to yield intermediate A8 (15.5 g, 95% yield) as a red
oil. The product was used in the next reaction without r purification. LCMS: 393
[M+NH4]+; R: 3.4 min (method 1).
Example A9
Preparation of intermediate A9: (R)-[3-(Zerl-butyloxycarbonyl)(3 -bromo-phenyl)
methyl-[1,1,3]oxathiazolidine-2,2-dioxide
O\\ /0
O N
04 Br
Ruthenium (III) chloride (85 mg, 0.41 mmol) was added to solution of intermediate
A8 (15.3 g, 40.8 mmol) in a mixture ofMeCN and H20 (1:1) (438 mL) at 0 °C,
followed by the addition of sodium periodate (13.1 g, 61.2 mmol). The reaction was
allowed to warm to room temperature and stirred for 2 hours. The mixture was filtered
through diatomaceous earth and washed with AcOEt (125 mL). H20 (125 mL) and
AcOEt (250 mL) were added to the filtrate. The c layer was separated, dried
(MgSO4), filtered and the solvents ated in vacuo. The product was purified by
flash column chromatography (silica gel, DCM). The d fractions were collected
and the solvents evaporated in vacuo to yield intermediate A9 (14.4 g, 90% yield) as a
white solid. LCMS: 409 ]+, R: 3.3 min (method 1), mp. 133.1 °C (FP90), cm:
-35.6 0 (589 nm, c 0.55 w/v%, DMF, 20 0C).
The following intermediate was ed ing to the synthetic ures
described in examples A7 - A9:
Example A10
Preparation of intermediate A10: rac-[3-(lerl—butyloxycarbonyl)(3 -nitro-phenyl)
methyl-[1,1,3]oxathiazolidine-2,2-dioxide
o\ /0
o”S‘N
1 p
o N?“
O 0.
Prepared from rac-[3 -(lerl—butyloxycarbonyl)(3 -nitro-phenyl)methyl-
[1,1,3]oxathiazolidineoxide. Flash column chromatography (silica gel, DCM) to
yield intermediate A10 as a yellow solid (95%). LCMS: 376 [M+NH4]+, R: 1.35 min
(method 2).
Example A11
Preparation of intermediate A11: 2-[2-(3-bromo-phenyl)-2R-ZerZ-butoxycarbonylamino-propyl
]-2H-pyrazolecarboxylic acid ethyl ester
W0 2012/117027
yoi::NH
Cesium carbonate (824 mg, 2.53 mmol) was added to a mixture of intermediate A9
(0.661 g, 1.69 mmol) and 2H-pyrazolecarboxylic acid ethyl ester (260 mg,
1.86 mmol) in DMSO (8 mL) at room temperature. The mixture was stirred at room
temperature for 30 min and at 110 °C for 3 hours. The mixture was treated with a
saturated on of citric acid and DCM (20 mL) and stirred for 2 hours. The organic
phase was separated and d with H20 (10 mL) and extracted with DCM
(2 x 10 mL). The organic layer was separated, dried (MgSO4), filtered and the solvents
evaporated in vacuo. The crude product was purified by flash column chromatography
(silica gel, DCM). The desired fractions were ted and the solvents evaporated in
vacuo to yield intermediate A11 (186 mg, 24% yield) as a colorless oil. LCMS: 452
[M+H]+, R: 4.23 min (method 3).
Example A12
Preparation of ediate A12: rac-[2-(4-bromo-pyrazolyl)methyl(3 phenyl
)-ethyl]-carbamic acid Zerl-butyl ester
Sodium carbonate (59 mg, 0.56 mmol) was added to a mixture of intermediate A10
(100 mg, 0.28 mmol) and 4-bromo-1H-pyrazole (53 mg, 0.36 mmol) in DMF (3 mL).
The mixture was stirred at 130 °C for 2 hours. The solvent was evaporated in vacuo.
The residue was treated with H20 (2 mL) and extracted with DCM (2 x 10 mL). The
organic layer was ted, dried (MgSO4), filtered and the solvents evaporated in
vacuo. The crude t was purified by flash column chromatography (silica gel,
DCM). The desired fractions were collected and the solvents evaporated in vacuo to
yield intermediate A12 (100 mg, 84% yield) as a white solid after treatment with cold
Eth. LCMS: 425 [M+H]+, R: 3.57 min (method 3), mp. 159.3 °C (PF 90).
e A13
Preparation of intermediate A13: (R)[2-amino(3 -bromo-phenyl)-propyl]-2H-
pyrazolecarboxylic acid ethyl ester
4‘! NH2
A0 0 .TFA
Trifluoroacetic acid (1 mL) was added to a stirred solution of intermediate A11 (186
mg, 0.41 mmol) in DCM (5 mL) at 0 °C. The mixture was stirred at room temperature
for 2 hours. The solvents were evaporated in vacuo to yield ediate A13 (180
mg, 94% yield) as a colorless oil that was used in the next step without further
purification. LCMS: 352 [M+H]+, R: 2.69 min (method 3).
Example A14
Preparation of intermediate A14: bromo[2-lerl—butoxycarbonylamino(3-
nitro-phenyl)-propyl]-2H-pyrazolecarboxylic acid
Br§N@\ N NH
HO C2 (,an
A 2 M solution of lithium diisopropylamide in THF and heptane (0.25 mL, 0.49 mmol)
was added to a solution of intermediate A12 (100 mg, 0.24 mmol) in THF (3 mL) at -
78 °C. The reaction mixture was stirred at -78 °C for 1 hour. Dry ice was then added
and the mixture was warm to room temperature over 2 hours. The mixture was treated
with a saturated solution of NH4C1 and extracted with DCM (3 x 10 mL). The c
layer was separated, dried, filtered and the solvents ated in vacuo. The crude
product was d by flash column chromatography (silica gel, MeOH/DCM). The
desired fractions were collected and the solvents evaporated in vacuo to yield
intermediate A14 (60 mg, 54% yield) as colourless oil. LCMS: 469 [M+H]+, R: 1.74
min (method 3).
Example A15
Preparation of intermediate A15: (3 -bromo-phenyl)methyl-6,7-dihydro-5H—
pyrazolo[1,5-a]pyrazinone
Potassium acetate (83 mg, 0.85 mmol) was added to a solution of intermediate A13
(180 mg, 0.39 mmol) in EtOH (5 mL) at room ature. The mixture was stirred at
90 °C for 5 hours. The solvent was evaporated in vacuo. The residue was treated with a
0.5 M aq. solution of HCl and extracted with DCM. The organic layer was separated,
dried (MgSO4), filtered and the solvents evaporated in vacuo. The crude t was
purified by flash column chromatography (silica gel, MeOH/DCM). The d
fractions were collected and the solvents evaporated in vacuo to yield intermediate
A15 (100 mg, 84% yield) as a colorless oil. LCMS: 306 [M+H]+, R: 2.01 min d
Example A16
Preparation of intermediate A16: racbromomethyl(3 -phenyl)-6,7-
o-5H-pyrazolo[l,5-a]pyrazinone
Method A
Trifluoroacetic acid (3 mL) was added to a solution of intermediate A14 (200 mg, 0.4
mmol) in DCM (20 mL). The mixture was stirred at room temperature for 2 hours.
Potassium acetate (59 mg, 0.06 mmol) in EtOH (3 mL) was then added. The mixture
was stirred at 90 °C for 3 hours. The solvents were evaporated in vacuo. The crude was
d with a l M aq. solution of HCl (10 mL) and the product extracted with AcOEt
(4 x 20 mL). The organic layer was separated, dried (MgSO4), filtered and the solvents
evaporated in vacuo. The crude product was purified by flash column chromatography
(silica gel, MeOH/DCM). The desired fractions were collected and the solvents
evaporated in vacuo to yield intermediate A16 (120 mg, 19% yield) as a white solid.
LCMS: 35l , R: 2.45 min (method 5), mp. 285.3 °C (FP 90).
Method B
Trifluoroacetic acid (100 mL) was added to a stirred solution of intermediate A23
(6.5 g, 13.07 mmol) in DCM (200 mL) at room temperature. The mixture was stirred at
room temperature for 3 hours. The solvent was evaporated in vacuo, then potassium
acetate (1.924 g, 19.60 mmoL) and EtOH (100 mL) were added, and the reaction
2012/053455
stirred at reflux for 4 hours. The crude was evaporated in vacuo and the residual treated
with a l M aq. on of HCl to pH = 3. The crude was extracted with AcOEt (3 X 50
ml), the organic phase was evaporated to dryness and the crude treated with cold EtOH
and Eth to afford ediate A16 as a beige solid. The combined solvents were
evaporated in vacuo and purified by column tography (silica gel; MeOH/DCM).
The desired fractions were collected and the solvents evaporated in vacuo to afford an
additional batch of intermediate A16 as a white solid (combined amount 4 g, 87%).
LCMS: 351 [M+H]+; R: 1.65 min (method 3).
Example A17
Preparation of ediate A17: (R)[3-(5-chloro-pyridinyl)-phenyl]methyl-
6,7-dihydro-5H—pyrazolo[l,5-a]pyrazinone
N. /
/ N |
_ \ N
Tetrakis(triphenylphosphine)palladium(0) (34 mg, 0.029 mmol) was added to a stirred
suspension of intermediate A15 (90 mg, 0.29 mmol) and ropyridineboronic
acid (55 mg, 0.35 mmol) in a mixture of 1,4-dioxane (5 mL) and a saturated solution of
Na2C03 (3 mL) at room temperature under N2. The mixture was stirred at 150 °C for 15
min under microwave irradiation. After cooling to room temperature, the mixture was
diluted with H20 and extracted with DCM. The organic layer was separated, dried
(MgSO4), filtered and the solvents evaporated in vacuo. The crude t was purified
by flash column chromatography (silica gel; MeOH/DCM). The desired fractions were
collected and the solvents evaporated in vacuo and washed with cold EtOH and Eth to
yield intermediate A17 (81 mg, 81% yield) as a white solid. LCMS: 339 [M+H]+; R:
0.89 min (method 2).
Example A18
Preparation of intermediate A18: [3-(5-chloro-pyridinyl)-phenyl]methyl-
6,7-dihydro-5H—pyrazolo[l,5-a]pyrazinethione
N. /
/ N |
_ \ N
Phosphoruspentasulflde (71 mg, 0.32 mmol) was added to a solution of intermediate
A17 (90 mg, 0.27 mmol) in pyridine (4 mL) and the mixture was heated at 100 °C for 5
hours. The t was evaporated in vacuo and the crude product was purified by short
column chromatography (silica gel, MeOH/DCM). The desired fractions were collected
and the solvents evaporated in vacuo to yield ediate A18 (60 mg, 63% yield) as
a yellow oil. LCMS: 355 , R: 2.4 min (method 3).
The following intermediates were prepared according to the synthetic procedure
described in example A18:
Example A19
Preparation of intermediate A19: racbromomethyl(3 -nitro-phenyl)-6,7-
dihydro-5H-pyrazolo[1, 5-a]pyrazinethione
Prepared from intermediate A16. Flash column chromatography (silica gel,
CM) to yield intermediate A19 as a yellow solid (87%). LCMS: 366
[M+H]+, R: 2.37 min (method 3).
Example A20
Preparation of intermediate A20: rac(3-amino-phenyl)bromomethyl-6,7-
dihydro-pyrazolo[1, 5-a]pyrazinylamine
32% Aq. NH3 solution (3 mL) was added to a stirred mixture of intermediate A19
(600 mg, 1.63 mmol) in a 7 M solution ofNH3 in MeOH (5 mL) in a sealed tube. The
mixture was stirred at 60 °C for 4 hours. After cooling to room ature the solvents
were evaporated in vacuo. The crude product was dissolved in EtOH (20 mL) and
2O tin(II) chloride (372 mg, 1.96 mmol) was added. The mixture was stirred at 90 °C for
24 hours. After cooling to room temperature, the e was filtered through celite
and the solvent evaporated in vacuo. The residue was treated with an 8% aq. solution of
NaOH (10 mL) and extracted with DCM (30 mL). The mixture was d at room
temperature for 1 hour. The organic layer was separated, dried (NaZSO4), filtered and
the ts evaporated in vacuo. The crude product was purified by flash column
chromatography (silica gel, 7 M on of NH3 in MeOH/DCM). The desired
fractions were collected and the solvents evaporated in vacuo to yield intermediate
A20 (200 mg; 38% yield) as a yellow oil. LCMS: 320 [M+H]+; R: 1.5 min (method 6).
Example A21
Preparation of intermediate A20: rac(3-amino-phenyl)bromomethyl-6;7-
dihydro-pyrazolo[1;5-a]pyrazinylamine and intermediate A21: racbromo
methyl(3-nitro-phenyl)-6;7-dihydro-pyrazolo[1;5-a]pyrazinylamine
NH2 \\
32% Aq. NH3 solution (4 mL) was added to a stirred e of intermediate A19
(3.8 g; 10.35 mmol) in a 7 M solution ofNH3 in MeOH (6 mL) in a sealed tube. The
mixture was stirred at 100 °C for 6 hours. After cooling to room temperature the
solvents were evaporated in vacuo. The crude product was purified by flash column
chromatography (silica gel; CM). The d ons were collected and the
solvents evaporated in vacuo and the crude product was purified by flash column
chromatography (silica gel; 7 M solution ofNH3 in MeOH/DCM). The desired
fractions were collected and the solvents evaporated in vacuo to yield intermediate 20
(100 mg; 3% ; ediate 21 (200 mg; 6% yield) and a fraction ning a
mixture of intermediate 20 and 21 (2.5 g). LCMS: A20: 322 ; R: 0.87 min
(method 3); A21: 350 [M+H]+; R: 0.95 min (method 2)
Example A22
Preparation of intermediate A22: rac(3-amino-phenyl)methyl-6;7-dihydro-
pyrazolo[1;5-a]pyrazinylamine
Method A
A solution of intermediate A20 (200 mg; 0.62 mmol) in MeOH (30 mL) and Et3N
(5 mL) was hydrogenated in a H-Cube reactor (1.2 mL/min; 30 mm palladium on
carbon 10% cartridge; full hydrogen mode; 50 °C; 3 cycles). The solvents were
concentrated in vacuo. The crude product was purified by flash column
chromatography (silica gel; 7 M solution of NH3 in MeOH/DCM). The desired
fractions were collected and the solvents evaporated in vacuo to yield intermediate 22
(100 mg, 66% yield) as a white solid. LCMS: 415 [M+H]+; R: 1.58 min (method 3).
Method B
Zinc (1.33 g, 20.40 mmol) was added to the fraction containing a e of
intermediates 20 and 21 described in Example A21 (2.5 g, 7.46 mmol) in EtOH
(100 mL) and AcOH (20 mL). The e was stirred at reflux for 24 hours. After
cooling to room temperature the mixture was filtered through celite and the solvents
evaporated in vacuo. The crude product was purified by flash column chromatography
(silica gel; 7 M solution ofNH3 in CM). The desired ons were collected
and the solvents evaporated in vacuo to yield intermediate 22 (0.93 g, 52% yield) as a
yellow oil that precipitates upon standing.
The following intermediates were prepared according to the synthetic procedure
bed in example A14, using ethyl chloroformate instead of dry ice:
Example A23
Preparation of intermediate A23: racbromo[2-tert-butoxycarbonylamino(3-
nitrophenyl)-propyl]-2H-pyrazolecarboxylic acid ethyl ester
Br4§\:'1l\ N NH
EtO C2 (3an
Prepared from intermediate A12. Flash column chromatography (silica gel;
AcOEt/heptane) to yield intermediate A23 (65%). LCMS: 499 ; R: 4.09 min
(method 3).
Example A24
Preparation of intermediate A24: rac-[1-methyl(3 -nitro-phenyl)(3 -trifluoromethylpyrazolyl
)-ethyl]-carbamic acid tert-butyl ester
Intermediate A10 (2.5 g, 6.976 mmol) was added to a d solution of 3-(trifluoro-
methyl)pyrazole (1.234 g, 9.069 mmol) and potassium carbonate (1.928 g,
13.952 mmol) in DMF (175 mL) at room temperature. The mixture was then heated at
2012/053455
110 °C for 2 hours. The solvent was evaporated and the residual treated with a saturated
solution of citric acid (80 mL) and AcOEt (160 mL). The mixture was d for 1 hour
at room temperature. The c layer was separated, dried and evaporated in vacuo.
The crude was purified by flash column chromatography (silica gel; DCM). The
desired fractions were collected and evaporated in vacuo to yield a transparent oil;
which, after treatment with cold Eth and standing; precipitated as a white solid (2 g;
69%).
Example A25
Preparation of intermediate A25: rac[2-tert-butoxycarbonylamino(3 -nitro-
phenyl)-propyl]trifluoromethyl-2H-pyrazolecarboxylic acid ethyl ester
O:N..f
\ r'u
Prepared from intermediate A24. Flash column chromatography (silica gel;
AcOEt/heptane) to yield intermediate A25 (51%). LCMS: 487 [M+H]+; R: 4.22 min
(method 3).
The following intermediate was prepared according to the synthetic procedure
described in example A16 — Method B:
e A26
Preparation of intermediate A26: racmethyl(3 -nitro-phenyl)trifluoromethyl-
6,7-dihydro-5H-pyrazolo[1,5-a]pyrazinone
Prepared from intermediate A25. Flash column chromatography (silica gel;
MeOH/DCM) to yield intermediate A26 as a white solid (93%). LCMS: 339 [M-H]';
R: 2.21 min (method 3).The following intermediate was prepared according to the
synthetic procedure bed in example A18 - A21:
Example A27
ation of intermediate A27: racmethyl(3 -nitro-phenyl)trifluoromethyl-
6,7-dihydro-5H-pyrazolo[1,5-a]pyrazinethione
Prepared from intermediate A26. Flash column chromatography (silica gel;
MeOH/DCM) to yield intermediate A27 as a yellow solid (95%). LCMS: 355 [M-H]';
R: 1.29 min d 2).
Example A28
Preparation of intermediate A28: rac(3-amino-phenyl)methyltrifluoromethyl-
6,7-dihydro-pyrazolo[l;5-a]pyrazinylamine and intermediate A29: 6-methyl(3-
nitro-phenyl)trifluoromethyl-6;7-dihydro-pyrazolo[ l ; 5 -a]pyrazinylamine
Prepared from intermediate A27. Flash column chromatography (silica gel;
MeOH/DCM) to yield intermediate A28 (16%) and intermediate A29 (59%). LCMS:
A28: 308 [M-H]'; R: 0.77 min (method 2); A29: 338 [M-H]'; R: 2.28 min (method 3);
e A29
Preparation of intermediate A28: (3-amino-phenyl)methyltrifluoromethyl-
6,7-dihydro-pyrazolo[ l ;5-a]pyrazinylamine
Iron (272 mg; 4.87 mmol) was added to a e of intermediate 29 (340 mg;
1 mmol) and NH4Cl (100 mg) in MeOH (20.4 mL) and H20 (6.8 mL). The reaction
was stirred at 80 °C for 5 hours. The crude was cooled and filtered over celite and the
solvent was evaporated in vacuo. The residue was d by flash column
chromatography (silica gel; 7 M solution ofNH3 in MeOH/DCM). The desired
fractions were collected and the solvents evaporated in vacuo to afford intermediate
28 as a transparent oil (260 mg; 84% yield). LCMS: 310 [M+H]+; R: 2.50 min (method
Following ediate A30 was prepared according to the synthetic procedures
described in examples Al - A4:
Example A30
Preparation of intermediate A30: racamino(5-bromofluoro-phenyl)-propan-l-
ol, intermediate A31: (R)amino(5-bromofluoro-phenyl)-propan-l-ol and
intermediate A32 (S) amino(5-bromofluoro-phenyl)-propan-l-ol:
R 8
OH OH OH
NH2 NH2 NH2
Br F Br F Br F
Prepared from l-(5-bromofluoro-phenyl)-ethanone.
This racemic material was then further purified by preparative SFC on Chiralpak
Diacel AD 20 um (2000 g), mobile phase (70% heptane, 30% EtOH with 0.1% Et3N).
The desired fractions for each enantiomer were collected and concentrated in vacuo to
yield intermediate A31 (44%) and intermediate A32 (44%).
The following intermediate was prepared according to the synthetic procedures
described in e A7 - A12:
Example A31
Preparation of intermediate A33: (R)-[l-(5-bromofluoro-phenyl)(4-fluoropyrazol-
l -yl)- l l-ethyl] -carbamic acid tert-butyl ester
\N NH
F \ N Br
Prepared from intermediate A31. Flash column chromatography (silica gel;
AcOEt/heptane) to yield intermediate A33 as a arent oil (55%). LCMS: 418
[M+H]+; R: 1.57 min d 2).
The following intermediate was prepared according to the synthetic procedure
described in example A25:
Example A32
Preparation of intermediate A34: (R)[2-(5-bromofluoro-phenyl)
tertbutoxycarbonylamino-propyl]fluoro-2H-pyrazolecarboxylic acid ethyl ester
ed from intermediate A33. Flash column chromatography (silica gel;
/heptane) to yield intermediate A34 as a transparent oil (67%). LCMS: 490
[M+H]+; R: 1.71 min (method 2).
The following intermediate was prepared according to the synthetic ure
described in example A16 - Method B:
Example A33
ation of intermediate A35: (R)(5-bromofluoro-phenyl)fluoromethyl-
6,7-dihydro-5H-pyrazolo[1,5-a]pyrazinone
Prepared from intermediate A34. Flash column chromatography (silica gel;
MeOH/DCM) to yield intermediate A35 as an oil (90%). LCMS: 343 [M+H]+; R:
0.96 min (method 2).
The following intermediate was prepared according to the synthetic procedure
bed in example A18:
Example A34
Preparation of intermediate A36: (R)(5-bromofluoro-phenyl)fluoromethyl-
6,7-dihydro-5H-pyrazolo[1,5-a]pyrazinethione
Prepared from intermediate A35. Flash column chromatography a gel,
MeOH/DCM) to yield intermediate A36 as a yellow solid (85%). LCMS: 360
[M+H]+, R: 1.19 min (method 2).
Example A35
Preparation of intermediate A37: (R)(5-bromofluoro-phenyl)fluoromethyl-
6,7-dihydro-pyrazolo[1,5-a]pyrazinylamine
32% Aq. NH3 solution (1.5 mL) and a 7 M on ofNH3 in MeOH (3 mL) were
added to intermediate A36 (330 mg, 0.921 mmol) at room temperature. The e
was stirred at 100 °C in a sealed tube for 6 hours, then, after cooling, the t was
removed in vacuo. The crude material was purified by column chromatography (silica
gel, MeOH/DCM). The desired fractions were collected to afford intermediate A37 as
a transparent oil (260 mg, 83%). LCMS: 343 [M+H]+, R: 1.03 min (method 2).
Example A36
Preparation of intermediate A38: (R)[5-(benzhydrylidene-amino)fluoro-phenyl]-
3-fluoromethyl-6,7-dihydro-pyrazolo[1,5-a]pyrazinylamine
Toluene (58 mL) was added to a mixture of intermediate A37 (3 g, 8.178 mmol),
ibenzylideneacetone)dipalladium (749 mg, 0.818 mmol), 2,2’-
bis(diphenylphosphino)-1,1’-binaphtyl (1.528 g, 2.453 mmol) and sodium tert-butoxide
(1.415 g, 14.72 mmol) in a sealed tube under N2 at room temperature. The mixture was
2O flushed with N2 for a few min and then benzophenoneimine (2.745 mL, 16.356 mmol)
was added and the mixture was stirred at 90 °C for 18 hours. The mixture was
concentrated in vacuo and then the mixture was diluted with H20 and extracted with
DCM. The organic layer was separated, dried (MgSO4), filtered and the solvent
concentrated in vacuo. The crude product was purified by flash column
chromatography (silica gel, MeOH/DCM). The desired ons were collected and
WO 17027
concentrated in vacuo to yield intermediate A38 as a pale yellow solid (3 g, 83%).
LCMS: 442 [M+H]+, R: 1.39 min (method 2).
Example A37
Preparation of intermediate A39: (R)(5-aminofluoro-phenyl)fluoromethyl-
6,7-dihydro-pyrazolo[1,5-a]pyrazinylamine
HCl 37% (1.05 mL) was added to a solution of ediate A38 (3 g, 6.795 mmol) in
iPrOH (78 mL). The mixture was stirred at room temperature for 2 hours. The e
was concentrated, and then triturated with EtzO. The solid was filtered off and taken on
iPrOH. NaHC03 (5.709 g) was added to it and the mixture stirred for 1 hour, then
filtered and the filtrate was concentrated in vacuo. The product was purified by flash
column chromatography (silica gel, CM). The desired fractions were collected
and concentrated in vacuo to yield pale a yellow oil. The material was treated with a
mixture /Eth 3:1 to afford intermediate A39 as a yellow solid (1.1 g, 58%).
LCMS: 278 [M+H]+, R: 0.56 min (method 2).
Example A38
Preparation of intermediate A40: (3-acetylfluoro-phenyl)-carbamic acid benzyl
ester
F NH Q
Benzyl chloroformate (3 mL, 21.5 mmol) was added to a mixture of 1-(5-amino
fluorophenyl)ethanone (3 g, 19.6 mmol) and tetrabutylammonium bromide at room
2O temperature. The reaction was stirred at room ature for 24 hours, the crude was
treated with AcOEt (50 mL) and H20 (50 mL), the organic phase was separated and
evaporated in vacuo. The crude was purified by column chromatography (silica gel,
MeOH/DCM). The desired fractions were collected and the solvents evaporated in
vacuo to afford intermediate A40 as a cream solid (4.7 g, 84%). LCMS: 286 [M-H]',
R: 2.81 min (method 3).
The following ediate was prepared ing to the synthetic procedure
described for the synthesis of intermediate A11:
Example A39
Preparation of intermediate A4 1: rac- { 3 -[2-(4-bromo-pyrazolyl)tertbutoxycarbonylaminomethyl-ethyl
]fluoro-phenyl}-carbamic acid ethyl ester
\N NH
Br \ NQDNHWOV
Prepared from intermediate A40. Flash column chromatography (silica gel,
AcOEt/heptane) followed by washing with DIPE to yield intermediate A41 as a white
solid (72%). LCMS: 487 , R: 3.56 min (method 3).
e A40
Preparation of intermediate A42: rac-ethyl 2-[2-[5-[bis(ethoxycarbonyl)amino]
fluoro-phenyl](tert-butoxycarbonylamino)propyl]bromo-pyrazole-3 -carboxylate
Lithium diisopropylamide (2 M in cyclohexane/ethylbenzene/THF, 7.36 mL, 14.721
mmol) was added to a stirred solution of intermediate A41 (2.1 g, 4.327 mmol) in dry
THF (66 mL) at -70 °C under N2 atmosphere. The e was stirred at -70 °C for 1
hour, then ethyl chloroformate (0.91 mL, 9.519 mmol) was added at -70 °C and the
reaction was warmed at -30 °C for 2 hours. The crude was quenched with a ted
on ofNH4C1 (30 mL) at -50 °C and warmed to room temperature, the crude was
extracted with AcOEt (3 x 20 mL), the organic phase was evaporated in vacuo, dried,
the resulting crude was purified by flash column chromatography (silica gel,
AcOEt/heptane). The desired fractions were collected and evaporated in vacuo to yield
intermediate A42 (1.6 g, 59%). LCMS: 631 [M+H]+, R: 4.22 min (method 3).
The following intermediate was prepared according to the synthetic procedure
described in example A16 — Method B:
Example A41
Preparation of intermediate A43: rac-ethyl N-[3-(3 methyloxo-5,7-
opyrazolo[1,5-a]pyrazinyl)fluoro-phenyl]-N-ethoxycarbonyl-carbamate
and intermediate A44: rac-ethyl N—[3-(3 -bromomethyloxo-5,7-
dihydropyrazolo[1,5-a]pyrazinyl)fluoro-phenyl]carbamate
_ 42 _
N yo
Wop NH
Prepared from intermediate A42. Flash column chromatography (silica gel;
AcOEt/heptane) to yield ediate A43 as a white solid (52%) and intermediate
A44 as a cream solid (20%). LCMS: A43: 485 [M+H]+; R: 2.15 min (method 3); A44:
413 [M+H]+; R: 0.98 min (method 2)
The following intermediate was prepared according to the tic procedure
bed in examples A18:
Example A42
Preparation of intermediate A45: rac-ethyl N—[3-(3 -bromomethylthioxo-5,7-
dihydropyrazolo[ l ; 5-a]pyrazinyl)fluoro-phenyl]-N-ethoxycarbonyl-carbamate
and intermediate A46: rac-ethyl N—[3-(3 -bromomethylthioxo-5,7-
opyrazolo[ l ; 5-a]pyrazinyl)fluoro-phenyl]carbamate
Prepared from intermediate A43 and A44. Flash column chromatography (silica gel;
MeOH/DCM) to yield intermediate A45 as a yellow solid (65%) and intermediate
A46 as a yellow solid (28%). LCMS: A45: 501 [M+H]+; R: 2.70 min (method 3); A46:
429 [M+H]+; R: 2.53 min (method 3)The following ediate was prepared
according to the synthetic procedure described in example A35:
Example A43
Preparation of intermediate A47: rac-[3-(4-aminobromomethyl-6;7-dihydro-
pyrazolo[l;5-a]pyrazinyl)—4-fluoro-phenyl]-carbamic acid ethyl ester
Prepared from intermediates A45 and A46. Flash column tography (silica gel;
MeOH/DCM) to yield intermediate A47 as a cream solid which was used as such in
WO 17027
the next step.The following intermediate was prepared ing to the synthetic
procedure described in example A22 — Method B:
Example A44
Preparation of intermediate A48: rac-[3-(4-aminomethyl-6,7-dihydro-pyrazolo
[l,5-a]pyrazinyl)fluoro-phenyl]-carbamic acid ethyl ester
Prepared from intermediate A47. Flash column chromatography (silica gel; 7 M
solution ofNH3 in MeOH/DCM) to yield intermediate A48 as an oil (71%). LCMS:
322 [M+H]+; R: 0.63 min d 2).
Example A45
Preparation of intermediate A49: 6-(5-aminofluoro-phenyl)methyl-6,7-dihydropyrazolo
[ l ,5-a]pyrazinylamine
Intermediate A48 (300 mg, 0.905 mmol) was added to a solution of HCl (6 M in H20
17.1 mL) at room temperature. The mixture was stirred at 110 °C for 35 hours, then the
solvent was removed in vacuo and treated with a saturated solution 03 and
extracted with AcOEt (3x 10 mL). The c layer was separated and evaporated in
vacuo. The crude al was purified by column chromatography (silica gel;
MeOH/DCM). The desired fractions were collected to intermediate A49 as a
transparent oil (160 mg, 68%). LCMS: 260 [M+H]+; R: 0.51 min d 3).
The following intermediate was prepared according to the synthetic procedure
described in example A8:
Example A46
Preparation of intermediate A50: rac(5-bromofluoro-phenyl)difluoromethyl-
2-oxo-21ambda*4*-[l,2,3]oxathiazolidinecarboxylic acid tert-butyl ester
Prepared from carbamic acid, N—[1-(5-bromofluorophenyl)-2,2-difluoro
(hydroxymethyl)ethyl]-, 1,1-dimethylethyl ester. Intermediate A50 obtained as a
yellow oil (crude al, e of diastereoisomers, 100%).
The following intermediate was prepared according to the synthetic procedure
described in example A9:
Example A47
Preparation of intermediate A51: rac(5-bromofluoro-phenyl)difluoromethyl-
oxo-2lambda*6*-[1,2,3]oxathiazolidinecarboxylic acid tert-butyl ester
0&6 CHF2
099” N
>|\ F
Prepared from intermediate A50. Trituration in heptane followed by column
chromatography (silica gel, DCM) to yield intermediate A51 as a white solid (78%).
LCMS: 465 ]+, R: 1.46 min (method 2).
Example A48
Preparation of intermediate A52: rac(5-bromofluoro-phenyl)-2,2-difluoro
(5 -methyl-3 -nitro-pyrazolylmethyl)-ethylamine
\\/NFF Br
EtOZC
To intermediate A51 (6.8 g, 15.238 mmol) and ethyl 5-nitro-1H-pyrazole
carboxylate (3.4 g, 18.365 mmol) in MeCN (150 mL) was added DBU (5.1 mL, 34.103
mmol) at room temperature. The resulting mixture was stirred at 60 °C for 18 hours.
The solvent was then evaporated in vacuo and to the residue was added HCl (4 M in
dioxane, 40 mL) at room temperature. The ing solution was stirred at room
temperature for 2 hours, then the solvent was evaporated in vacuo. H20 and sat.
Na2C03 were added to the residue, and the mixture extracted with DCM. The c
layer was dried (Na2S04), filtered and the solvents evaporated in vacuo. The crude
WO 17027
product was purified by flash column chromatography (silica gel; DCM in heptane
50/50). The desired fractions were collected and evaporated in vacuo to yield
intermediate 52 as a sticky foam (4.6 g; 67%). LCMS: 453 [M+H]+; R: 1.46 min
(method 2).
Example A49
Preparation of intermediate A53: (5-bromofiuoro-phenyl)difiuoromethyl-
2-nitro-6;7-dihydro-5H-pyrazolo[1;5-a]pyrazinone
DBU (4.126 mL; 27.6 mmol) was added to a stirred e of intermediate A52
(4.15 g; 9.198 mmol) in MeCN (45 mL) in a sealed tube. The mixture was stirred at
150 0C for 30 min under microwave irradiation. The mixture was diluted with 10%
NH4Cl and extracted with DCM. The organic layer was dried (NaZSO4); filtered and the
solvent evaporated in vacuo. The residue was purified by flash column chromatography
(silica gel; AcOEt). The desired fractions were collected and evaporated in vacuo to
yield intermediate A54 (2.48 g; 67%). LCMS: 405 [M-H]'; R: 1.10 min (method 2).
Example A50
Preparation of intermediate A54: racamino(5-bromofiuoro-phenyl)
difiuoromethyl-6;7-dihydro-5H-pyrazolo[1;5-a]pyrazinone
H2N N
Intermediate A53 (2.4 g; 5.924 mmol) was dissolved in MeOH (150 mL). The
solution was hydrogenated with R1102 cartridge (50 °C; filll en, 1 ml/min). The
solvent was evaporated in vacuo and the e purified by flash column
tography (silica gel; MeOH/DCM). The desired fractions were collected and
concentrated in vacuo to yield intermediate A54 as an ite solid (2.1 g; 94%).
LCMS: 377 [M+H]+; R: 0.74 min (method 2).
Example A51
Preparation of intermediate A55: rac(5-bromofiuoro-phenyl)difiuoromethyl-
6,7-dihydro-5H-pyrazolo[1;5-a]pyrazinone
A mixture of intermediate A54 (1.8 g, 4.798 mmol), EtOH (36 mL) and H2804
(0.767 mL) was heated to 90 °C. Sodium nitrite (828 mg, 11.995 mmol) was then added
portionwise and the mixture was stirred at 90 °C for 20 min. Then, the mixture was
cooled to room temperature, poured into sat. Na2C03 and H20 and extracted with
DCM. The organic layer was separated, dried (Na2S04), filtered and the solvents
ated in vacuo. The crude product was d by flash column chromatography
(silica gel, MeOH/DCM). The desired fractions were collected and concentrated in
vacuo to yield intermediate A55 as a white solid (1.25 g, 72%). LCMS: 403
[M+MeCN+H]+, R: 0.92 min (method 2).
The following intermediate was prepared according to the synthetic procedure
described in examples A18:
Example A52
Preparation of ediate A56: (5-bromofluoro-phenyl)difluoromethyl-
6,7-dihydro-5H-pyrazolo[1,5-a]pyrazinethione
ed from intermediate A55. Flash column chromatography (silica gel, DCM) to
yield intermediate 56 as a yellow solid (1.14 g, 88%). LCMS: 419 [M+MeCN+H]+,
R: 1.19 min (method 2).
Example A53
Preparation of intermediate A57: rac(5-bromofluoro-phenyl)difluoromethyl-
2O 6,7-dihydro-pyrazolo[1,5-a]pyrazinylamine
N CHF2
NH2 F
A solution of intermediate 56 (1.12 g, 2.977 mmol) in 7 M NH3 in MeOH (30 mL)
was stirred under microwave irradiation for 30 min at 120 °C. The solvent was
evaporated in vacuo and the residue treated with DCM and washed with diluted
Na2C03 solution. The organic layer was separated, dried (Na2S04), filtered and the
solvents evaporated in vacuo. The crude product was purified by flash column
chromatography (silica gel; 7 M solution of NH3 in MeOH/DCM). The desired
fractions were ted and trated in vacuo to yield intermediate 57 as a
yellow solid (1.03 g, 96%). LCMS: 361 [M+H]+; R: 0.99 min (method 2).
The following intermediate was prepared according to the synthetic procedures
described in examples A36 - A37:
Example A54
Preparation of intermediate A58: rac(5-aminofluoro-phenyl)difluoromethyl-
6,7-dihydro-pyrazolo[1,5-a]pyrazinylamine
\ CHE
—N NH2
NH2 F
Prepared from intermediate A54. Flash column chromatography (silica gel; 7 M NH3
in MeOH/DCM) to yield ediate 58 as an off-white foam (86%). LCMS: 296
; R: 0.61 min d 2).
Example A5 5
Preparation of intermediate A59: 1H-pyrazole-3,5-dicarboxylic acid diamide
CONH2
\ N
H2NOC
Diethylpyrazole-3,5-dicarboxylate (5.2 g, 24.5 mmol) was dissolved in a 7 M NH3 in
MeOH and the mixture was heated at 70 °C in a sealed tube for 48 hours. The solvent
was then evaporated to give intermediate A59 (3.74 g, 99%) as a solid.
Example A56
Preparation of intermediate A60: 1H-pyrazole-3,5-dicarbonitrile
Phosphorus oxychloride (11.249 mL, 9 mmol) was added to a mixture of
2O intermediate 59 (3.72 g, 24.136 mmol) in MeCN (90 mL) at 0 °C. The mixture was
stirred in a sealed tube at 120 °C for 5 hours (until the solid disappeared). The reaction
was poured in a mixture of ice/ H20 and ted with DCM. The organic layer was
separated, dried (NaZSO4), filtered and the solvents evaporated in vacuo to give
intermediate A60 as a solid, which was used in next step without further purification.
LCMS: 117 [M-H]'; R: 0.61 min (method 2).
The following intermediate was prepared according to the synthetic procedures
bed in examples A7 - A12:
Example A57
Preparation of intermediate A61: (R)-[1-(5-bromofluoro-phenyl)(3,5-dicyanopyrazolyl
)methyl-ethyl]-carbamic acid tert-butyl ester
NC 0%
\ N NH
\ N Br
Prepared from intermediate A31. Flash column chromatography (silica gel;
AcOEt/DCM) to yield intermediate A61 as a foam (60%). LCMS: 467 [M+NH4]+; R:
1.57 min (method 2).
Example A58
ation of intermediate A62: (R)amino(5-bromofluorophenyl)methyl-
hydro-pyrazolo[1,5-a]pyrazinecarbonitrile
To a stirred mixture of intermediate A61 (4.483 g, 8.4 mmol) in DCM (40 mL) at
room temperature was added trifluoroacetic acid (4 mL). The mixture was stirred for 20
hours at room temperature, then basif1ed with a sat.solution 03 and extracted
with DCM. The organic layer was separated, dried (MgSO4), filtered and concentrated
in vacuo. The residue was purified by flash column chromatography (silica gel; 7 N
NH3 in MeOH/DCM). The d fractions were collected and concentrated in vacuo
to give intermediate A62 (2.9 g, 99%). LCMS: 349 ; R: 1.13 min (method 2).
Example A59
Preparation of intermediate A63: (R)amino(5-aminofluorophenyl)methyl-
6,7-dihydro-pyrazolo[1,5-a]pyrazinecarbonitrile
The on was set-up in two equal batches. The total amount ofmaterial used is
ed CuI (342 mg, 1.795 mmol) was added to a sion of intermediate A62
(500 mg, 1.436 mmol), sodium azide (284 mg, 4.308 mmol),
N,N’-dimethylethylenediamine (255 uL, 2.369 mmol) and Na2CO3 (457 mg, 4.308
mmol) in MeCN (10 mL) and the reaction was degassed. The mixture was heated at
110 0C for 4 hours, then at 120 °C for additional 2 hours. The mixture was then
quenched with 1 M HCl and the water layer was basified with NH4OH and extracted
with AcOEt (3x). The combined organic layers were dried ), filtered and
concentrated. The crude t was purified by flash column chromatography (silica
gel, 7 N solution ofNH3 in MeOH/DCM). The desired fractions were collected and
concentrated in vacuo to yield intermediate A63 (300 mg, 65%). LCMS: 285 [M+H]+,
R: 0.74 min (method 2).
The following intermediate was prepared according to the synthetic procedures
described in examples A7 - A9, A11, A13 and A15:
Example A60
Preparation of intermediate A64: (R)(5-bromofluoro-phenyl)methyloxo-
4 5 6 7-tetrahydro-pyrazolo[1,5-a]pyrazinecarboxylic acid ethyl ester
7 7 7
Prepared from diethylpyrazole-3,5-dicarboxylate. Intermediate A64 used as a crude
white solid in the subsequent reaction.
Example A61
Preparation of ediate A65: (R)(5-bromofluoro-phenyl)hydroxymethyl-
6-methyl-6,7-dihydro-5H-pyrazolo[1,5-a]pyrazinone
Sodium borohydride (3.094 g, 81.774 mmol) was added to a stirred solution of
intermediate 64 (3.6 g, 9.086 mmol) in THF (10 mL) and MeOH (5 mL) at 0 °C. The
mixture was stirred at room temperature for 18 hours. The mixture was cooled to 0 °C,
treated with H20 and extracted with DCM. The organic layer was dried (NaZSO4),
filtered and the t evaporated in vacuo to yield intermediate A65 (3.2 g, 99%) as
a white solid.
e A62
Preparation of intermediate A66: (R)(5-bromofiuoro-phenyl)methyloxo-
4,5,6,7-tetrahydro-pyrazolo[l,5-a]pyrazinecarbaldehyde
Manganese dioxide (7 g, 80.5 mmol) was added to a solution of intermediate A65
(3.2 g, 9.035 mmol) in chloroform (48 mL).The reaction mixture was stirred at 62 °C
for 4 hours. The mixture was filtered h celite and washed with DCM. The
organic layer was concentrated to yield intermediate A66 as a light orange fluffy solid
(2.3 g, 72%).
Example A63
Preparation of intermediate A67: (R)(5-bromofiuoro-phenyl)difiuoromethyl-
6-methyl-6,7-dihydro-5H-pyrazolo[ l ,5-a]pyrazinone
A solution of intermediate A66 (2.3 g, 6.531 mmol) in DCM (50ml) and DAST (2. 193
mL, 16.328 mmol) in DCM (50ml) were pumped h a flow try tec
R2+R4 modulardeVice, coil 10 mL at 80 °C, Rt = 15 min. The outlet solution was
collected over C21CO3. The solution was filtered through celite and washed with DCM,
the organic layer was washed with a sat. solution ofNaHC03 and extracted with DCM.
The organic layer was dried over NaZSO4, filtered and concentrated in vacuo to yield
intermediate A67 (2.2 g, 90%) as a brown oil.
Example A64
Preparation of intermediate A68: (R)(5-bromofiuoro-phenyl)difiuoromethyl-
6-methyl-6,7-dihydro-5H-pyrazolo[ l ,5-a]pyrazinethione
.5].
Phosphoruspentasulfide (1.871 g, 8.419 mmol) was added to a solution of
ediate A67 (2.1 g, 5.613 mmol) in dioxane (1 mL) and the mixture was heated
at 100 °C for 18 hours. The mixture was concentrated in vacuo and d by flash
column chromatography (silica gel; DCM). The desired fractions were collected and
concentrated in vacuo to yield intermediate A68 (2 g, 91%) as a yellow oil. LCMS:
392 [M+H]+; R: 1.29 min (method 2).
Example A65
Preparation of ediate A69: (R)(5-bromofiuoro-phenyl)difiuoromethyl-
6-methyl-6,7-dihydro-pyrazolo[1,5-a]pyrazinylamine
The reaction was set-up in two equal batches. The total amount ofmaterial used is
reported NH3 (2 M in EtOH, 30 mL, 60 mmol) was added to intermediate A69
(2 g, 5.125 mmol) and NH4Cl (2.173 g, 41 mmol). The mixture was heated under
microwave irradiation at 170 °C for 45 min. The mixture was concentrated, and another
mL ofNH3 (2 M in EtOH) were added. The e was heated under microwave
irradiation at 170 °C for 45 min. This procedure was repeated 4 times for a total amount
of time of 180 min. The mixture was filtered and the filtrate was concentrated in vacuo.
The crude was d by flash column chromatography (silica gel; MeOH/DCM). The
desired fractions were collected and concentrated in vacuo to yield intermediate A69
(1 g, 52%) as an oil. LCMS: 375 [M+H]+; R: 1.11 min (method 2).
The following intermediate was prepared according to a synthetic procedures similar to
the one described in example A59:
Example A66
Preparation of intermediate A70: (R)(5-aminofiuoro-phenyl)difiuoromethyl-
6-methyl-6,7-dihydro-pyrazolo[1,5-a]pyrazinylamine
2012/053455
Prepared from intermediate A69. Flash column chromatography (silica gel;
MeOH/DCM) to yield intermediate A70 as an oil (51%). LCMS: 310 [M+H]+; R:
0.69 min (method 2).
The following intermediate was ed according to a tic procedures similar to
the one described in examples A7 - A11, A48, A15 and A18:
Example A67
Preparation of intermediate A71: (R)(5-bromofluoro-phenyl)fluoro-2,6-
dimethyl-6,7-dihydro-5H-pyrazolo[1,5-a]pyrazinethione
Prepared from omethyl-1H-pyrazolecarboxylic acid ethyl ester. Flash
column chromatography (silica gel; AcOEt/DCM) to yield intermediate A71 as a
yellow solid (92%). LCMS: 374 [M+H]+; R: 1.27 min (method 2).
Example A68
Preparation of intermediate A72: (5-bromofluoro-phenyl)fluoro-2,6-
dimethyl-6,7-dihydro-pyrazolo[1,5-a]pyrazinylamine
NH3 (2 M in EtOH, 10 eq) was added to a solution of intermediate 71 (2.4 g, 6.448
mmol) and NH4Cl (4 eq.) and the mixture was heated at 85 °C in a sealed tube for 24
hours. The solvent was evaporated in vacuo and the residue suspended in DCM and
washed with H20. The organic layer was separated, dried (MgSO4), filtered and the
solvents evaporated in vacuo. To the residue more NH4Cl (4 eq.) followed by NH3
(2 M in EtOH, 10 eq), were added and the mixture was heated at 85 °C in a sealed tube
for 24 hours. This process was repeated four more times for a total amount ofNH3 (2
M in EtOH) of 276 mL, and 8.277 g ofNH4Cl. The t was then purified by flash
column chromatography a gel, MeOH/DCM). The desired fractions were collected
and concentrated in vacuo to yield intermediate A72 (960 mg, 42%) as a pale yellow
solid. LCMS: 357 [M+H]+, R: 1.11 min d 2).
The following intermediate was prepared according to a synthetic procedures similar to
the one described in examples A36 - A37:
Example A69
Preparation of ediate A73: (R)(5-aminofluoro-phenyl)fluoro-2,6-
dimethyl-6,7-dihydro-pyrazolo[1,5-a]pyrazinylamine
Prepared from intermediate A72. Flash column chromatography (silica gel, 7 N NH3
in MeOH/DCM) to yield intermediate A73 as a pale yellow solid (42%).
The ing intermediate was prepared according to a synthetic procedures similar to
the one described in examples A7 — A9, A48, A23, Al6B. A18, A21, A36, A37:
e A70
Preparation of intermediate A74: (R)(5-aminofluoro-phenyl)chloromethyl-
6,7-dihydro-pyrazolo[1,5-a]pyrazinylamine
Prepared from intermediate A31. Flash column chromatography (silica gel,
2O MeOH/DCM) followed by trituration in DIPE/Eth to yield ediate A74 as a
yellow solid (94%). LCMS: 294 [M+H]+, R: 1.13 min (method 3).
Preparation of the final compounds
Example B1
Preparation of compound 1: (R)[3-(5-chloro-pyridinyl)-phenyl]methyl-6,7-
dihydro-pyrazolo[1,5-a]pyrazinylamine trifluoroacetate salt
_ 54 _
N\ /
/ N |
_ \ N
A 32% aq. NH3 solution (0.5 mL) was added to a stirred mixture of intermediate A18
(60 mg, 0.17 mmol) in a 7 M solution of NH3 in MeOH (1.5 mL) in a sealed tube. The
mixture was stirred at 100 °C for 5 hours. After cooling to room ature, the
solvents were evaporated in vacuo. The crude product was purified by short column
chromatography (silica gel, MeOH/DCM). The desired fractions were collected and
concentrated in vacuo to give a fraction that was further purified by reverse phase
HPLC (Gradient from 80% 0.1% TFA solution in H20, 20% CH3CN to 0% 0.1% TFA
solution in H20, 100% CH3CN).and triturated with DIPE to yield compound 1 (36 mg,
46% yield) as a white solid. 1H NMR (500 MHz, DMSO-d6) 6 ppm 1.79 (s, 3 H), 4.69
(d, J=13.6 Hz, 1 H), 5.25 (d, J=13.9 Hz, 1 H), 7.23 (d, J=2.3 Hz, 1 H), 7.45 (br. d,
J=8.7 Hz, 1 H), 7.52 (t, J=7.8 Hz, 1 H), 7.69 (d, J=2.0 Hz, 1 H), 7.75 (br. d, J=7.8 Hz,
1 H), 7.94 — 7.96 (m, 1 H), 8.28 (t, J=2.2 Hz, 1 H), 8.66 (d, J=2.3 Hz, 1 H), 8.88 (d,
J=2.0 Hz, 1 H), 9.28 (br. s, 1 H), 9.87 (br. s, 1 H), 11.06 (br. s, 1 H).
Example B2
Preparation of compound 2: racchloro-pyridinecarboxylic acid [3-(4-amino
methyl-6,7-dihydro-pyrazolo[1,5-a]pyrazinyl)-phenyl]-amide
-Chloro-pyridinecarboxylic acid (71.8 mg, 0.68 mmol) was added to a solution of
-dimethoxy-1,3,5-triazinyl)methylmorpholinium chloride (137 mg,
0.5 mmol) in MeOH (4 mL). The mixture was stirred at room temperature for 5 min.
Then the mixture was cooled to 0 °C and a solution of intermediate A22 (100 mg,
0.41 mmol) in MeOH (3 mL) was added. The mixture was warmed to room
temperature and stirred for 3 hours. The mixture was treated with a ted solution
ofNa2C03 and H20 and extracted with DCM. The organic layer was separated, dried
4), filtered and the solvents evaporated in vacuo. The crude product was
triturated with Et2O and then was purified by flash column chromatography (silica gel,
MeOH/DCM). The desired fractions were collected and the ts evaporated in
vacuo and the resulting fraction was further d by flash column chromatography
a gel, MeOH/DCM). The desired fractions were collected and the solvents
evaporated in vacuo to yield compound 2 (21 mg, 13% yield) as a white solid. 1H
NMR (500 MHz, CDC13) 5 ppm 1.67 (s, 3 H), 4.38 (d, J=13.3 Hz, 1 H), 4.53 (d, J=13.3
Hz, 1 H), 4.79 (br. s, 2H), 6.72 (br. s, 1 H), 7.24 (br. d, J=7.8 Hz, 1 H), 7.34 (t, J=7.9
Hz, 1 H), 7.51 (d, J=2.0 Hz, 1 H), 7.73 (dd, J=8.1, 1.2 Hz, 1 H), 7.85 — 7.90 (m, 2 H),
8.23 (d, J=8.4 Hz, 1 H), 8.55 (d, J=2.0 Hz, 1 H), 9.86 (br. s, 1 H).
Example B3
Preparation of compound 3: rac-3,5-dichloro-pyridinecarboxylic acid [3-(4-amino-
6-methyl-6,7-dihydro-pyrazolo[1,5-a]pyrazinyl)-phenyl]-amide
Cl Cl
1:“Wmm
I N
/ O
3,5-Dichloro-pyridinecarboxylic acid (112 mg, 0.58 mmol) was added to a solution
of 4-(4,6-dimethoxy-1,3,5-triazinyl)methylmorpholinium de (176.2 mg,
0.64 mmol) in MeOH (5 mL). The mixture was stirred at room temperature for 5 min.
Then the mixture was cooled to 0 °C and a solution of intermediate A22 (128 mg,
0.53 mmol) in MeOH (5 mL) was added. The mixture was warmed to room
temperature and stirred for 3 hours. The mixture was treated with a saturated solution
ofNa2C03 and H20 and extracted with DCM. The organic layer was ted, dried
(MgSO4), filtered and the solvents evaporated in vacuo. The crude product was d
by flash column chromatography (silica gel, MeOH/DCM). The d ons were
collected and the ts evaporated in vacuo. The crude product was triturated with
Eth and then was purified by flash column chromatography (silica gel, MeOH/DCM).
The desired fractions were collected and the solvents evaporated in vacuo to yield
compound 3 (180 mg, 82% yield) as a white solid. 1H NMR (500 MHz, DMSO-d6) 6
ppm 1.41 (s, 3 H), 4.12 — 4.45 (m, 2 H), 6.54 (br. s., 2 H), 6.64 (d, J=2.0 Hz, 1 H), 7.25
— 7.32 (m, 2 H), 7.45 (d, J=2.0 Hz, 1 H), 7.63 (m, J=6.3, 2.5, 2.5 Hz, 1 H), 7.82
(br. s, 1 H), 8.43 (d, J=2.0 Hz, 1 H), 8.72 (d, J=2.0 Hz, 1 H), 10.64 (br. s., 1 H).
Example B4
Preparation of compound 4: (R*)—3,5-dichloro-pyridinecarboxylic acid [3-(4-amino-
6-methyl-6,7-dihydro-pyrazolo[1,5-a]pyrazinyl)-phenyl]-amide and compound 5:
(S*)-3,5-dichloro-pyridinecarboxylic acid [3-(4-aminomethyl-6,7-dihydropyrazolo
[1,5-a]pyrazinyl)-phenyl]-amide
CI CI CI CI
N\ / N\ /
/ N | / N |
1c \ \
_ H / _ 8* H
N N
/N /N
o o
H2N H2N
A sample of compound 3 (0.58 g) was washed with cold DCM and then with Eth.
This c compound was then separated into the corresponding enantiomers by
preparative SFC on Chiralpak AD-H 511m (250 X 20 mm), mobile phase (0.3% iPrNHg,
60% C02, 40% EtOH). The desired fractions for each enantiomer were collected and
concentrated in vacuo to yield compound 4 (152 mg, 26% . 1H NMR (500 MHz,
DMSO-d6) 5 ppm 1.41 (s, 3 H), 4.28 (br. s, 2 H), 6.41 (br. s., 2 H), 6.64 (d, J=1.4 Hz,
1 H), 7.30 (s, 2 H), 7.45 (d, J=2.0 Hz, 1 H), 7.60 — 7.67 (m, 1 H), 7.83 (s, 1 H), 8.44
(d, J=2.0 Hz, 1 H), 8.73 (d, J=2.3 Hz, 1 H), 10.65 (br. s., 1 H) and compound 5
(155 mg, 27% yield) 1H NMR (500 MHz, DMSO-d6) 5 ppm 1.41 (s, 3 H), 4.28
(s, 2 H), 6.41 (br. s., 2 H), 6.64 (d, J=O.9 Hz, 1 H), 7.26 — 7.33 (m, 2 H), 7.45
(d, J=1.4 Hz, 1 H), 7.59 — 7.69 (m, 1 H), 7.84 (s, 1 H), 8.44 (d, J=2.0 Hz, 1 H), 8.73
(d, J=2.0 Hz, 1 H), 10.65 (br. s., 1 H) both as white solids.
Example B5
Preparation of compound 6: raccyano-pyridinecarboxylic acid [3-(4-amino
methyl-6,7-dihydro-pyrazolo[1,5-a]pyrazinyl)-phenyl]-amide and compound 7:
(R*)cyano-pyridinecarboxylic acid [3-(4-aminomethyl-6,7-dihydropyrazolo
[1,5-a]pyrazinyl)-phenyl]-amide and compound 8: (S*)—5-cyano-pyridine-
2-carboxylic acid [3-(4-aminomethyl-6,7-dihydro-pyrazolo[1,5-a]pyrazinyl)-
phenyl]-amide
WNN wNyG/K wNyQ/KON\ / N\ / N\ /
/ N H I / N H I / N H I
\ \ \
O O
HZN HZN HZN
5-Cyano-pyridinecarboxylic acid (187.8 mg, 1.27 mmol) was added to a solution of
-dimethoxy-1,3,5-triazinyl)methylmorpholinium chloride (412.9 mg,
1.49 mmol) in MeOH (20 mL). The mixture was stirred at room temperature for 5 min.
Then the mixture was cooled to 0 °C and a solution of intermediate A22 (300 mg,
1.24 mmol) in MeOH (10 mL) was added. The mixture was warmed to room
temperature and stirred for 4 hours. The mixture was treated with a saturated solution
ofNa2C03 and H20 and extracted with DCM. The organic layer was ted, dried
), filtered and the solvents ated in vacuo. The crude product was d
by flash column chromatography a gel, MeOH/DCM). The desired fractions were
collected and the solvents evaporated in vacuo. The crude product was triturated with
Eth and then was purified by flash column chromatography (silica gel, 7 M solution
ofNH3 in MeOH/DCM). The desired fractions were collected and the ts
evaporated in vacuo. The crude product was washed with EtOH and Eth and then
purified by flash column chromatography (silica gel, MeOH/DCM). The desired
W0 2012/117027 2012/053455
fractions were collected and the solvents evaporated in vacuo to yield compound 6
(122 mg, 26% yield) as a cream solid. 1H NMR (500 MHz, DMSO-d6) 5 ppm 1.42
(s, 3 H), 4.31 (m, J=3.5 Hz, 2 H), 6.66 (br. s, 2 H), 6.66 (d, J=1.7 Hz, 1 H), 7.26 — 7.33
(m, 2 H), 7.45 (d, J=2.0 Hz, 1 H), 7.78 (dt, J=6.9, 1.9 Hz, 1 H), 8.01 — 8.06 (m, 1 H),
8.29 (dd, J=8.1, 0.6 Hz, 1 H), 8.59 (dd, J=8.1, 2.0 Hz, 1 H), 9.18 — 9.22 (m, 1 H), 10.68
(s, 1 H). This c compound was then further purified by preparative SFC on
Chiralpak AD-H 511m (250 X 20 mm), mobile phase (0.3% , 60% C02, 40%
EtOH). The desired fractions for each enantiomer were collected and concentrated in
vacuo to yield compound 7 (45.8 mg, 10% yield) 1H NMR (500 MHz, DMSO-d6) 5
ppm 1.41 (s, 3 H), 4.21 — 4.35 (m, 2 H), 6.39 (br. s., 2 H), 6.64 (br. s, 1 H), 7.26 — 7.35
(m, 2 H), 7.45 (d, J=1.2 Hz, 1 H), 7.78 (br. d, J=7.2 Hz, 1 H), 8.05 (br. s, 1 H), 8.30
(d, J=8.1 Hz, 1 H), 8.60 (dd, J=8.1, 2.0 Hz, 1 H), 9.20 — 9.22 (m, 1 H), 10.68 (s, 1 H)
and compound 8 (46.5 mg, 10% yield) 1H NMR (500 MHz, DMSO-d6) 5 ppm 1.41
(s, 3 H), 4.29 (br. s., 2 H), 6.41 (br. s., 2 H), 6.64 (d, J=1.7 Hz, 1 H), 7.27 — 7.34
(m, 2 H), 7.45 (d, J=1.7 Hz, 1 H), 7.77 — 7.80 (m, 1 H), 8.05 (br. s, 1 H), 8.30
(dd, J=8.2, 0.7 Hz, 1 H), 8.60 (dd, J=8.1, 2.0 Hz, 1 H), 9.19 — 9.24 (m, 1 H), 10.68
(s, 1 H), both as white solids.
Example B6
Preparation of compound 9: raccyano-pyridinecarboxylic acid amino
bromomethyl-6,7-dihydro-pyrazolo[1,5-a]pyrazinyl)-phenyl]-amide
trifluorocetate salt
N\ /
/ NMH I
Br /N U N\[/l:l\l\/Kc!
-Cyano-pyridinecarboxylic acid (23.6 mg, 0.16 mmol) was added to a solution of
4-(4,6-dimethoxy-1,3,5-triazinyl)methylmorpholinium chloride (51.9 mg,
0.19 mmol) in MeOH (5 mL). The mixture was stirred at room temperature for 5 min.
Then the mixture was cooled to 0 °C and a solution of intermediate A20 (50 mg,
0.16 mmol) in MeOH (5 mL) was added. The mixture was warmed to room
temperature and stirred for 4 hours. The e was treated with a saturated solution
ofNa2C03 and H20 and extracted with DCM. The organic layer was separated, dried
(MgSO4), filtered and the solvents evaporated in vacuo. The crude product was d
by flash column chromatography (silica gel, MeOH/DCM). The desired fractions were
collected and the solvents evaporated in vacuo. The crude t was triturated with
Eth and then was purified by flash column chromatography (silica gel, MeOH/DCM).
The desired fractions were collected and concentrated in vacuo and the residue was
W0 2012/117027
purified by ative HPLC (RP C18 XSelect 19 x 100 5 um), mobile phase (gradient
from 80% 0.1% TFA solution in H20, 20% CH3CN to 0% 0.1% TFA solution in H20,
100% CH3CN) to yield compound 9 (9.8 mg, 11% yield) as a white solid. 1H NMR
(500 MHz, DMSO-d6) 5 ppm 1.75 (s, 3 H), 4.74 (d, J=13.9 Hz, 1 H), 5.09 (d, J=13.6
Hz, 1 H), 7.19 — 7.24 (m, 1 H), 7.40 (t, J=8.1 Hz, 1 H), 7.87 (dd, J=8.1, 1.2 Hz, 1 H),
7.88 (s, 1 H), 8.00 (br. s, 1 H), 8.29 (dd, J=8.1, 0.6 Hz, 1 H), 8.60 (dd, J=8.4, 2.0 Hz,
1 H), 8.78 (br. s., 1 H), 9.21 (dd, J=2.0, 0.9 Hz, 1 H), 9.70 (br. s., 1 H), 10.89 (s, 1 H),
11.23 (br. s., 1 H).
Example B7
Preparation of compound 10: rac-3,5-dichloro-pyridinecarboxylic acid [3-(4-amino-
6-methyltrifluoromethyl-6,7-dihydro-pyrazolo[1,5-a]pyrazinyl)-phenyl]-amide
and compound 11: (R*)-3,5-dichloro-pyridinecarboxylic acid [3-(4-amino
trifluoromethyl-6,7-dihydro-pyrazolo[ 1 , 5-a]pyrazinyl)-phenyl]-amide and
compound 12: (S*)-3,5-dichloro-pyridinecarboxylic acid [3-(4-aminomethyl
trifluoromethyl-6,7-dihydro-pyrazolo[1,5-a]pyrazinyl)-phenyl]-amide
CIWCI CIWCI CI CI
F3C N myN N W
T/ ‘N H J \N H J Fscj/ \N H
_/ N \ _/ R* N \ _/ N \ J
\ 8*
N N \ N
/N I /N /N |
/ o O / O
H2N H2N H2N
chloropyridinecarboxylic acid (70 mg, 0.366 mmol) was added to a solution
of 4-(4,6-dimethoxy-1,3,5-triazinyl)methylmorpholinium chloride (119 mg,
0.431 mmol) in MeOH (5 mL). The mixture was stirred at room temperature for 5 min.
Then the mixture was cooled to 0 °C and a solution of intermediate A28 (111 mg,
0.359 mmol) in MeOH (5 mL) was added. The e was warmed to room
temperature and stirred for 4 hours. The mixture was treated with a saturated solution
ofNa2C03 and H20 and extracted with DCM. The organic layer was separated, dried
), filtered and the solvents evaporated in vacuo. The crude product was purified
by flash column chromatography (silica gel, MeOH/DCM). The d fractions were
collected and the solvents evaporated in vacuo. The crude product was triturated with
Et2O, sonicated, filtered and dried in vacuo at 50°C to yield compound 10 (95 mg,
55% yield) as a white solid. This racemic compound was then r purified by
preparative SFC on Chiralpak AD-H 5pm (250 x 20 mm), mobile phase (0.3% iPrNH2,
70% CO2, 30% iPrOH). The desired fractions for each enantiomer were collected and
concentrated in vacuo to yield compound 11 (40 mg, 23% yield). 1H NMR (400 MHz,
DMSO-d6) 5 ppm 1.42 (s, 3 H), 4.35 — 4.47 (m, 2 H), 6.61 (br. s., 2 H), 7.09 (br. s, 1 H),
7.26 — 7.35 (m, 2 H), 7.59 — 7.67 (m, 1 H), 7.83 (br. s, 1 H), 8.43 (d, J=2.1 Hz, 1 H),
8.72 (d, J=2.1 Hz, 1 H), 10.67 (s, 1 H) and compound 12 (38 mg, 22% yield), for
which the 1H NMR was in agreement with the one of compound 11.
Example B8
ation of compound 13: (R)methoxy-pyrazinecarboxylic acid [3-(4-amino-
3-fiuoromethyl-6,7-dihydro-pyrazolo[ l ,5-a]pyrazinyl)fiuoro-phenyl]-amide
-Methoxypyrazinecarboxylic acid (120 mg, 0.78 mmol) was added to a solution of
4-(4,6-dimethoxy-l,3,5-triazinyl)methylmorpholinium chloride (233 mg,
0.841 mmol) in MeOH (5 mL). The mixture was stirred at room temperature for 5 min.
Then the mixture was cooled to 0 °C and a solution of intermediate A39 (212 mg,
0.764 mmol) in MeOH (5 mL) was added. The mixture was warmed to room
temperature and stirred for 4 hours. The mixture was treated with a saturated on
ofNa2C03 and H20 and extracted with DCM. The organic layer was separated, dried
(MgSO4), filtered and the solvents evaporated in vacuo. The crude product was purified
by flash column chromatography (silica gel, MeOH/DCM). The desired fractions were
collected and the solvents evaporated in vacuo. The crude product was ated with
Eth and then was purified by flash column chromatography (silica gel, MeOH/DCM).
The desired fractions were collected and concentrated in vacuo to afford a white solid.
The solid was treated with DIPE to afford compound 13 (155 mg, 49%) as a white
solid. 1H NMR (500 MHz, CDC13) 5 ppm 1.59 (s, 3 H), 4.06 (s, 3 H), 4.28
(br. d, J=13.0 Hz, 1 H), 4.51 (br. d, J=13.0 Hz, 1 H), 5.04 (br. s., 2 H), 7.09 (dd,
J=11.6, 9.0 Hz, 1 H), 7.36 (d, J=4.0 Hz, 1 H), 7.84 — 7.97 (m, 2 H), 8.12 (d, J=1.2 Hz,
1 H), 8.99 (d, J=1.2 Hz, 1 H), 9.51 (br. s, 1 H).
Example B9
Preparation of compound 14: rac-3,5-dichloro-pyridinecarboxylic acid [3-(4-amino-
6-methyl-6,7-dihydro-pyrazolo[ l , 5-a]pyrazinyl)fiuoro-phenyl]-amide and
nd 15: (R*)—3,5-dichloro-pyridinecarboxylic acid [3-(4-aminomethyl-
6,7-dihydro-pyrazolo[1,5-a]pyrazinyl)—4-fiuoro-phenyl]-amide and compound 16:
(S*)-3,5-dichloro-pyridinecarboxylic acid aminomethyl-6,7-dihydropyrazolo
[l,5-a]pyrazinyl)fiuoro-phenyl]-amide
N\ CIWCI N\ CIWC N\ CIWCI
f N H H N H H N H
—/ N f
\N/ —/ R* N f J
\N/ —/ 3* N \N
WM 0 WM 0 WM 0
H2N F H2N F H2N F
3,5-Dichloropyridinecarboxylic acid (75.5 mg, 0.393 mmol) was added to a on
of 4-(4,6-dimethoxy-l,3,5-triazinyl)methylmorpholinium chloride (128 mg,
0.463 mmol) in MeOH (5 mL). The mixture was stirred at room temperature for 5 min.
W0 2012/117027
Then the mixture was cooled to 0 °C and a solution of intermediate A49 (100 mg,
0.386 mmol) in MeOH (5 mL) was added. The mixture was warmed to room
temperature and stirred for 4 hours. The mixture was treated with a saturated solution
ofNa2C03 and H20 and extracted with DCM. The organic layer was separated, dried
(MgSO4), filtered and the solvents evaporated in vacuo. The crude product was purified
by flash column chromatography (silica gel, MeOH/DCM). The desired fractions were
collected and the solvents evaporated in vacuo. The crude product was triturated with
Et2O, sonicated, d and dried in vacuo at 50°C. The resulting compound was
purified one addition time by flash column tography (silica gel, MeOH/DCM)
to yield, after treatment with AcOEt and DIPE, compound 14 (95 mg, 57% yield) as a
white solid. This racemic compound was then fiirther purified by preparative SFC on
Chiralcel OJ-H 5 um (250 x 20 mm), mobile phase (0.3% iPrNH2, 85% CO2, 15%
EtOH). The desired fractions for each enantiomer were collected and concentrated in
vacuo to yield compound 15 (38 mg, 23% yield). 1H NMR (400 MHz, CDCl3) 5 ppm
1.58 (s, 3 H), 2.52 (br. s., 2 H), 4.41 (br. d, J=13.2 Hz, 1 H), 4.62 (dd, J=13.2, 0.9 Hz,
1 H), 6.43 (d, J=2.1 Hz, 1 H), 7.08 (dd, J=11.7, 8.9 Hz, 1 H), 7.52 (d, J=2.1 Hz, 1 H),
7.81 (dd, J=6.9, 2.8 Hz, 1 H), 7.89 (d, J=2.1 Hz, 1 H), 7.94 (ddd, J=8.8, 4.1, 3.0 Hz,
1 H), 8.42 (d, J=2.1 Hz, 1 H), 9.71 (br. s., l H) and compound 16 (40 mg, 24% ,
for which the 1H NMR was in agreement with the one of compound 15.
Example B 10
ation of compound 17: racmethoxy-pyrazinecarboxylic acid [3-(4-amino-
6-difluoromethyl-6,7-dihydro-pyrazolo[ l , 5-a]pyrazinyl)fluoro-phenyl]-amide and
nd 18: (R*)—5-methoxy-pyrazinecarboxylic acid [3-(4-amino
difluoromethyl-6,7-dihydro-pyrazolo[ l , 5-a]pyrazinyl)fluoro-phenyl]-amide and
compound 19: -methoxy-pyrazinecarboxylic acid [3-(4-amino
diNfluoromethyl-6, 7-//dihydro-pyrazolo[Cl, 5-a]pyrazinyl)Nfluoro-phenyl]-amideVOMe VOMe VOMe
-Methoxypyrazinecarboxylizc acid (187.9 mg, 1.219 mmle) was added to a mixture
of 4-(4,6-dimethoxy-l,3,5-triazinyl)methylmorpholinium chloride (337 mg,
1.219 mmol) in MeOH (6 mL). The e was d at room temperature for 5 min.
Then the mixture was cooled to 0 °C and a solution of intermediate A58 (300 mg,
1.016 mmol) in MeOH (4 mL) was added. The mixture was warmed to room
temperature and stirred for 1 hour, then treated with a saturated solution ofNa2C03 and
H20 and extracted with DCM. The organic layer was separated, dried (MgSO4), filtered
and the ts evaporated in vacuo. Part of the product was precipitated with DCM
W0 17027
and the remaning crude material purified by flash column chromatography (silica gel,
7 M NH3 in MeOH/DCM). The desired fractions were collected and the ts
evaporated in vacuo. The resulting product was combined with the one obtained from
precipitation and triturated with heptane, ted and filtered, to afford compound 17
(278 mg, 62% yield) as a white solid. This racemic compound was then further d
by preparative SFC on Chiralcel OD-H 5 pm (250 x 20 mm), mobile phase (0.3%
iPrNHg, 70% C02, 30% EtOH). The desired fractions for each enantiomer were
collected and concentrated in vacuo to yield compound 18 (103 mg, 23% yield).
1H NMR (500 MHz, DMSO-d6) 5 ppm 4.03 (s, 3 H) 4.58 (br. d, J=13.6 Hz, 1 H) 4.75
(br. d, J=13.6 Hz, 1 H) 6.27 (t, J=55.5 Hz, 1 H) 6.68 (d, J=2.0 Hz, 1 H) 6.93 (br. s, 2 H)
7.20 (dd, J=11.8, 9.0 Hz, 1 H) 7.48 (d, J=2.0 Hz, 1 H) 7.78 (dt, J=8.4, 3.6 Hz, 1 H)
8.17 (dd, J=7.1, 2.7 Hz, 1 H) 8.42 (d, J=1.2 Hz, 1 H) 8.88 (d, J=1.2 Hz, 1 H) 10.51
(s, l H) and compound 19 (102 mg, 23% yield), for which the 1H NMR was in
agreement with the one of compound 18.
Example B1 1
Preparation of compound 20: racfiuoro-pyridinecarboxylic acid [3-(4-amino
difiuoromethyl-6,7-dihydro-pyrazolo[ l , 5-a]pyrazinyl)fiuoro-phenyl]-amide and
compound 21: (S*)fiuoro-pyridinecarboxylic acid [3-(4-aminodifiuoromethyl-
6,7-dihydro-pyrazolo[1,5-a]pyrazinyl)fiuoro-phenyl]-amide and compound 22:
(R*)fiuoro-pyridinecarboxylic acid [3-(4-aminodifiuoromethyl-6,7-dihydropyrazolo
[l,5-a]pyrazinyl)fiuoro-phenyl]-amide
N /\/F N /\/F N /\/F
f ‘N CHF2 H /J V \N CHF2 H \N CHF2 H
—/ N \N —/ 3* N /J V
\N —/ R* N /J
WM 0 WM 0 WM 0
H2N F H2N F H2N F
-Fluoropyridinecarboxylic acid (74.5 mg, 0.528 mmol) was added to a mixture of
4-(4,6-dimethoxy-l,3,5-triazinyl)methylmorpholinium chloride (146 mg,
0.528 mmol) in MeOH (3 mL). The mixture was stirred at room temperature for 5 min.
Then the mixture was cooled to 0 °C and a solution of intermediate A58 (130 mg,
0.44 mmol) in MeOH (2 mL) was added. The mixture was warmed to room
temperature and stirred for 1 hour, then treated with a saturated on ofNa2C03 and
H20 and extracted with DCM. The organic layer was separated, dried (MgSO4), filtered
and the solvents evaporated in vacuo. The crude product was purified by flash column
chromatography (silica gel, 7 M NH3 in MeOH/DCM). The desired ons were
collected and the ts evaporated in vacuo. The ing t was triturated
with heptane, sonicated and filtered, to afford compound 17 (112 mg, 60% yield) as a
white solid. This c compound was then filrther purified by preparative SFC on a
Chiralpak AD-H column (5 um, 250 x 20 mm), mobile phase [70% C02, 30% EtOH
(+ 0.3% iPrNH2)]. The desired ons for each enantiomer were collected and
concentrated in vacuo to yield compound 21 (41 mg, 22% yield), for which the 1H
NMR was in agreement with the one of compound 22, and compound 22 (43 mg,
23% yield). 1H NMR (400 MHz, 6) 5 ppm 4.53 — 4.61 (m, 1 H), 4.74
(br. d, J=13.4 Hz, 1 H), 6.26 (t, J=55.9 Hz, 1 H), 6.67 (d, J=1.8 Hz, 1 H), 6.93
(br. s, 2 H), 7.20 (dd, J=12.0, 9.0 Hz, 1 H), 7.47 (d, J=1.8 Hz, 1 H), 7.79 (ddd, J=8.8,
3.9, 2.8 Hz, 1 H), 7.98 (td, J=8.7, 2.9 Hz, 1 H), 8.16 (dd, J=7.1, 2.7 Hz, 1 H), 8.21
(dd, J=8.8, 4.6 Hz, 1 H), 8.73 (d, J=2.8 Hz, 1 H), 10.62 (br. s, 1 H).
Example B12
Preparation of compound 23: (R)methoxy-pyrazinecarboxylic acid [3-(4-amino-
2-cyanomethyl-6,7-dihydro-pyrazolo[ l ,5-a]pyrazinyl)fluoro-phenyl]-amide
NC /N\N O\
H2N F
-Methoxypyrazinecarboxylic acid (95.4 mg, 0.619 mmol) was added to a mixture
of 4-(4,6-dimethoxy-l,3,5-triazinyl)methylmorpholinium chloride (171.3 mg,
0.619 mmol) in MeOH (3 mL). The mixture was stirred at room temperature for 30
min, then it was cooled to 0 °C and a solution of intermediate A63 (160 mg,
0.563 mmol) in MeOH (3 mL) was added. The mixture was warmed to room
temperature and stirred for 20 hour, then treated with a ted solution ofNa2C03
and stirred for few minutes. The mixture was then extracted with DCM. The organic
layer was separated, dried (MgSO4), filtered and the solvents evaporated in vacuo. The
crude product was purified by flash column tography (silica gel, MeOH/DCM).
The desired fractions were collected and the solvents evaporated in vacuo, to afford
after drying compound 23 (115 mg, 49% yield) as a solid. 1H NMR (500 MHz, CDCl3)
ppm 1.58 (s, 3 H), 1.66 (br. s., 2 H), 4.07 (s, 3 H), 4.47 (br. d, J=13.6 Hz, 1 H),
4.66 (br. d, J=13.3 Hz, 1 H), 6.81 (br. s, 1 H), 7.09 (dd, J=11.6, 9.0 Hz, 1 H),
7.75 — 7.81 (m, 1 H), 7.97 (dd, J=7.1, 2.7 Hz, 1 H), 8.14 (s, 1 H), 9.00 (s, 1 H), 9.49
(br. s., l H).
Example B13
Preparation of nd 24: (R)fluoro-pyridinecarboxylic acid [3-(4-amino
cyanomethyl-6,7-dihydro-pyrazolo[l,5-a]pyrazinyl)fluoro-phenyl]-amide
NC N /
/ \N I
— R NH
H2N F
-Fluoropyridinecarboxylic acid (87.4 mg, 0.619 mmol) was added to a e of
4-(4,6-dimethoxy-1,3,5-triazinyl)methylmorpholinium chloride (171.3 mg,
0.619 mmol) in MeOH (3 mL). The e was stirred at room temperature for 30
min, then it was cooled to 0 °C and a solution of intermediate A63 (160 mg,
0.563 mmol) in MeOH (3 mL) was added. The mixture was warmed to room
temperature and stirred for 20 hour, then treated with a saturated solution of Na2C03
and stirred for few min. The mixture was then extracted with DCM. The organic layer
was separated, dried (MgSO4), filtered and the solvents evaporated in vacuo. The crude
product was purified by flash column chromatography (silica gel, MeOH/DCM). The
desired ons were collected and the solvents evaporated in vacuo, to afford an oil
that was ated with DIPE. The resulting solid was filtered and dried to give
compound 24 (95 mg, 41% yield) as a solid. 1H NMR (400 MHz, CDCl3) 6 ppm 1.58
(br. s, 3 H) 4.46 (br. d, J=13.4 Hz, 1 H) 4.66 (d, J=13.4 Hz, 1 H) 4.90 (br. s., 2 H) 6.81
(s, 1 H) 7.10 (dd, J=11.8, 8.8 Hz, 1 H) 7.60 (td, J=8.3, 2.8 Hz, 1 H) 7.78 — 7.86 (m, 1 H)
7.96 (dd, J=7.1, 2.7 Hz, 1 H) 8.32 (dd, J=8.7, 4.5 Hz, 1 H) 8.45 (d, J=2.8 Hz, 1 H) 9.80
(br. s, 1 H).
Example B 14
Preparation of compound 25: (R)difluoromethyl-1H-pyrazolecarboxylic acid [3-
(4-aminocyanomethyl-6,7-dihydro-pyrazolo[1,5-a]pyrazinyl)fluoro-
phenyl]-amide
NC /N\
— R
/ N NHHLN\</N\ F
H2N F
1-Difluoromethyl-1H-pyrazolecarboxylic acid (82.7 mg, 0.51 mmol) was added to a
mixture of 4-(4,6-dimethoxy-1,3,5-triazinyl)methylmorpholinium chloride
(155 mg, 0.561 mmol) in MeOH (3 mL). The mixture was stirred at room temperature
for 30 min, then it was cooled to 0 °C and a solution of intermediate A63
(145 mg, 0.51 mmol) in MeOH (3 mL) was added. The mixture was warmed to room
temperature and d for 3 hour, then treated with a saturated solution of Na2C03 and
stirred for few min. The e was then extracted with DCM. The organic layer was
separated, dried (MgSO4), d and the solvents evaporated in vacuo. The crude
product was purified by flash column chromatography (silica gel, MeOH/DCM). The
desired ons were collected and the solvents evaporated in vacuo, to afford an oil
that was triturated with heptane. The resulting solid was filtered and dried to give
compound 25 (100 mg, 46% yield) as a solid. 1H NMR (500 MHz, CDCl3) 5 ppm 1.58
(s, 3 H) 4.47 (br. d, J=13.3 Hz, 1 H) 4.65 (d, J=13.3 Hz, 1 H) 4.94 (br. s., 2 H) 6.81
(s, 1 H) 7.05 (d, J=2.6 Hz, 1 H) 7.09 (dd, J=11.6, 9.0 Hz, 1 H) 7.20 (t, J=60.4 Hz, 1 H)
7.69 — 7.75 (m, 1 H) 7.88 (d, J=2.6 Hz, 1 H) 7.91 (dd, J=6.8, 2.2 Hz, 1 H) 8.62 (br. s,
1 H).
Example B 1 5
Preparation of compound 26: (R)cyano-pyridinecarboxylic acid [3-(4-amino
6-methyl-6,7-dihydro-pyrazolo[1,5-a]pyrazinyl)fluoro-phenyl]-amide
NCW/N‘N
— R NHfl\
H2N F
-Cyanopyridinecarboxylic acid (79.7 mg, 0.538 mmol) was added to a mixture of
4-(4,6-dimethoxy-1,3,5-triazinyl)methylmorpholinium chloride (163.8 mg,
0.592 mmol) in MeOH (3 mL). The mixture was stirred at room ature for 30
min, then it was cooled to 0 °C and a solution of intermediate A63 (153 mg,
0.538 mmol) in MeOH (3 mL) was added. The mixture was warmed to room
temperature and stirred for 3 hour, then treated with a saturated solution ofNa2C03 and
stirred for few min. The mixture was then extracted with DCM. The organic layer was
ted, dried (MgSO4), filtered and the solvents evaporated in vacuo. The crude
product was purified by flash column chromatography (silica gel, MeOH/DCM). The
desired fractions were collected and the solvents evaporated in vacuo, to afford an oil
that was triturated with heptane. The resulting solid was filtered and dried to give
nd 26 (63 mg, 28% yield) as a solid. 1H NMR (500 MHz, DMSO-d6) 6 ppm
1.47 (br. s, 3 H) 4.43 — 4.55 (m, 2 H) 6.76 (br. s., 2 H) 7.20 (dd, J=11.8, 9.0 Hz, 1 H)
7.27 (br. s, 1 H) 7.71 — 7.79 (m, 1 H) 8.10 (br. d, J=5.2 Hz, 1 H) 8.26 (d, J=8.1 Hz, 1 H)
8.57 (dd, J=8.2, 1.6 Hz, 1 H) 9.18 (br. s, 1 H) 10.81 (br. s, 1 H).
Example B 16
ation of compound 27: (R)fluoro-pyridinecarboxylic acid amino
difluoromethylmethyl-6,7-dihydro-pyrazolo[1,5-a]pyrazinyl)fluoro-phenyl]-
amide
-Fluoropyridinecarboxylic acid (68 mg, 0.485 mmol) was added to a mixture of
4-(4,6-dimethoxy-1,3,5-triazinyl)methylmorpholinium chloride (148 mg,
0.533 mmol) in MeOH (3 mL). The mixture was stirred at room temperature for 5 min,
then it was cooled to 0 °C and a solution of intermediate A70 (150 mg, 0.485 mmol) in
MeOH (2 mL) was added. The mixture was warmed to room temperature and stirred
for 4 hours, then concentrated in vacuo in a cold bath. The crude product was purified
by flash column chromatography (dry load, silica gel, MeOH/DCM). The desired
fractions were collected and the solvents evaporated in vacuo, to afford an off-white
solid, that was further purified by RP HPLC on C18 Sunf1re (30 x 100 5um). Mobile
phase: nt from 80% 0.1% TFA solution in H20, 20% CH3CN to 0% 0.1% TFA
solution in H20, 100% CH3CN, yielding compound 27 (57 mg, 33%) as a white solid.
1H NMR (500 MHz, DMSO-d6) 5 ppm 1.84 (br. s, 3 H), 4.79 (br. d, J=13.9 Hz, 1 H),
5.02 (br. d, J=13.3 Hz, 1 H), 7.10 (t, J=54.3 Hz, 1 H), 7.30 (dd, J=12.0, 8.8 Hz, 1 H),
7.46 (br. s., 1 H), 7.86 — 7.91 (m, 1 H), 7.93 (dd, J=7.5, 2.3 Hz, 1 H), 7.98 (td, J=8.7,
2.9 Hz, 1 H), 8.20 (dd, J=8.7, 4.6 Hz, 1 H), 8.73 (d, J=2.9 Hz, 1 H), 9.33 (br. s., 1 H),
.07 (br. s., 1 H), 10.80 (br. s, 1 H), 11.09 (br. s., 1 H).
Example B 17
Preparation of compound 28: (R)methoxy-pyrazinecarboxylic acid [3-(4-amino-
2-difluoromethylmethyl-6,7-dihydro-pyrazolo[1,5-a]pyrazinyl)fluoro-phenyl]-
amide
R NHfl/l;/NIrO\
-Methoxypyrazinecarboxylic acid (75 mg, 0.485 mmol) was added to a e of
4-(4,6-dimethoxy-1,3,5-triazinyl)methylmorpholinium chloride (148 mg,
0.533 mmol) in MeOH (3 mL). The mixture was d at room temperature for 5 min,
then it was cooled to 0 °C and a solution of intermediate A70 (150 mg, 0.485 mmol) in
MeOH (2 mL) was added. The mixture was warmed to room temperature and stirred
for 4 hours, then concentrated in vacuo in a cold bath. The crude product was d
by flash column chromatography (dry load, silica gel, MeOH/DCM). The desired
fractions were collected and the solvents evaporated in vacuo, to afford an off-white
solid, that was further purified by RP HPLC on C18 e (30 x 100 5um). Mobile
phase: gradient from 80% 0.1% TFA solution in H20, 20% CH3CN to 0% 0.1% TFA
solution in H20, 100% CH3CN, yielding nd 27 (32 mg, 12%) as a white solid.
1H NMR (500 MHz, DMSO-d6) 5 ppm 1.85 (br. s., 3 H) 4.03 (s, 3 H) 4.80
(br. (1, J=l3.9 Hz, 1 H) 5.03 (br. (1, J=l2.7 Hz, 1 H) 7.12 (t, J=54.3 Hz, 1 H) 7.31
(dd, J=11.8, 9.0 Hz, 1 H) 7.47 (br. s., 1 H) 7.84 — 7.90 (m, 1 H) 7.96 (dd, J=7.4, 2.2 Hz,
1 H) 8.42 (d, J=1.4 Hz, 1 H) 8.88 (d, J=1.4 Hz, 1 H) 9.32 (br. s., 1 H) 10.09 (br. s., 1 H)
.70 (s, 1 H) 11.08 (br. s., 1 H).
Example B 1 8
Preparation of compound 29: (R)methoxy-pyrazinecarboxylic acid [3-(4-amino-
3-fiuoro-2,6-dimethyl-6,7-dihydro-pyrazolo[1,5-a]pyrazinyl)fiuoro-phenyl]-
amide
/N\N
NH(ENick
H2N F
-Methoxypyrazinecarboxylic acid (97 mg, 0.631 mmol) was added to a mixture of
4-(4,6-dimethoxy-1,3,5-triazinyl)methylmorpholinium chloride (175 mg,
0.631 mmol) in MeOH (2 mL). The mixture was d at room temperature for 5 min,
then it was cooled to 0 °C and a solution of intermediate A73 (175 mg, 0.601 mmol) in
MeOH (2 mL) was added. The mixture was warmed to room temperature and stirred
for 24 hours, The solvent was removed in vacuo and the residue was suspended in
DCM and treated with sat. Na2CO3. The organic layer was ted, dried (MgSO4),
filtered and concentrated in vacuo. The crude t was purified by flash column
tography (silica gel, 7 M NH3 in MeOH/DCM). The d fractions were
collected and the solvents evaporated in vacuo. The residue was suspended in EtzO.
The precipitate was filtered off and dried under vacuum at 50°C to yield compound 29
(195 mg, 76%) as a white solid. 1H NMR (500 MHz, DMSO-d6) 5 ppm 1.45
(br. s, 3 H), 2.12 (s, 3 H), 4.02 (s, 3 H), 4.18 (br. d, J=13.0 Hz, 1 H), 4.24 (br. d, J=12.4
Hz, 1 H), 6.26 (br. s., 2 H), 7.17 (dd, J=12.0, 8.8 Hz, 1 H), 7.68 — 7.77 (m, 1 H), 8.04
(br. d, J=5.2 Hz, 1 H), 8.40 (d, J=1.2 Hz, 1 H), 8.87 (d, J=1.2 Hz, 1 H), 10.46
(br. s, 1 H).
Table 1
C4Stereochemistry/
salt
R / CF3COOH
2012/053455
_ 67 _
EX. I C4Stere0chemistry/
><H ---L-Ar
No. salt
IIw 0E 0E (/3
IIww 0E OE m
IIw4; 0E O
IIw4; 0E 0E *
IIwU} 0E O (I)
U} 0E OE 66
0E O
HI OE OE RS / CF3COOH
y—x O \l OS“ OE OE (I)
IIw\l 0:11 0E 0E 66
y—x IIw\l OS“ 0E OE (I) %
y—x IIw00 OE OE
.1; II 01 OE (I)
U: II 0'11 OE 66
y—x O\ HI O’11 OE (I) %
_ 68 _
IIIIIII-IIIEX.1 2 3 C4Stere0chemistry/
II Pd(/3
(I) 66
Pd(/3
III W66
IIII (I) 66
IIIIIII
IIIII
I 0F IICH
0F II0"11 0E R / CF3COOH
R / CF3COOH
0F II0 0E
0F IIOE W(I)
0F II0E ”3*
0F II0E 73
_ 69 _
,M .0U)85g(DE.E“
i.’CD'1
mm N O O'11 0E 76
m N O ’11 0E w
N 0F ’11 0E w
wN 0F 0 0E w
93 \l w[\J 0 0 I2 w
B2 0 O OE w
m\o 0 0 '11 OE w
O\ 0 0 ’11 0E w
N 0 0 ’11 0E 76(/3
N 0 0 ’11 0E w
0 0F ’11 0E w
C. cal Part
Nuclear Ma netic Resonance NMR
1H NMR spectra were recorded either on a Bruker DPX-4OO or on a Bruker
AV-SOO spectrometer with standard pulse sequences, operating at 400 MHz and 500
MHz respectively. Chemical shifts (6) are reported in parts per million (ppm)
downfield from tetramethylsilane (TMS), which was used as internal standard
ethod
For (LC)MS-characterization of the compounds of the present invention, the
following methods were used.
WO 17027
General procedure A [or Acquity—Sg 2D instrument
The UPLC (Ultra Performance Liquid Chromatography) measurement was
performed using an Acquity UPLC (Waters) system comprising a r organizer, a
binary pump with degasser, a four column’s oven, a diode-array detector (DAD) and a
column as specified in the respective methods. The MS detector was configured with
an electrosprayionization . Mass spectra were acquired on a single quadrupole
SQD or by scanning from 100 to 1000 in 0.1 second using an channel delay
of 0.08 second. The capillary needle voltage was 3.0 kV. The cone voltage was 25 V
for positive ionization mode and 30 V for negative tion mode. Nitrogen was used
as the nebulizer gas. The source temperature was maintained at 140 oC. Data
acquisition was performed with MassLynX-OpenlynX software.
Method 1:
In addition to the general procedure A: Reversed phase UPLC was carried out on a
BEH-C18 column (1.7 um, 2.1 X 50 mm) from Waters, with a flow rate of 1.0 ml/min,
at 50°C without split to the MS detector. The nt conditions used are: 95 % A
(0.5 g/l ammonium acetate solution + 5 % acetonitrile), 5 % B (acetonitrile), to 40 % A,
60 % B in 3.8 minutes, to 5 % A, 95 % B in 4.6 minutes, kept to 5.0 s. Injection
volume 2.0 ul.
Method 2.‘
In addition to the general procedure A: Reversed phase UPLC was carried out on a
RRHD Eclipse Plus-C18 (1.8 um, 2.1 X 50 mm) from Agilent, with a flow rate of
1.0 ml/min, at 50°C without split to the MS detector. The gradient conditions used are:
95 % A (0.5 g/l ammonium acetate solution + 5 % acetonitrile), 5 % B nitrile), to
40 % A, 60 % B in 1.2 minutes, to 5 % A, 95 % B in 1.8 minutes, kept to 2.0 minutes.
Injection volume 2.0 ul.
Method 3:
Same gradient as method 1; column used: RRHD Eclipse Plus-C18 (1.8 um, 2.1 X
50 mm) from Agilent.
General procedure B [or HP 1100-MS instruments (TOF or MSD)
, Sg 2D
The HPLC measurement was performed using an HP 1100 (Agilent
Technologies) system comprising a pump (quaternary or binary) with degasser, an
autosampler, a column oven, a diode-array detector (DAD) and a column as specified
in the respective s. The MS detector (SQD, TOF or MSD) was configured with
either an electrospray ionization source or an ESCI dual tion source (electrospray
combined with atmospheric pressure chemical ionization). en was used as the
nebulizer gas. The source temperature was maintained either at 140°C or 100°C. Data
_ 7] _
acquisition was performed either with MassLynX-OpenlynX software or tion-
Agilent Data Browser software.
Bl: Mass spectra were acquired on a single quadrupole MSD detector in APCI mode
by scanning from 100 to 1000 in 0.99 s, step size of 0.30 and peak width of 0. 10
minutes. The capillary needle voltage was 3.0 Kv, the fragmentor voltage was 70V for
positive and negative tion modes and the Corona ity was 4 uA.
B2: Mass spectra were acquired on a single quadrupole SQD detector by scanning from
100 to 1000 in 0.1 second using an inter-channel delay of 0.08 second. The capillary
needle voltage was 3.0 kV. The cone voltage was 20 V for positive ionization mode
and 30 V for ve ionization mode.
B3: Mass spectra were acquired on a Time of Flight (TOF) detector by scanning from
100 to 750 in 0.5 seconds using a dwell time of 0.3 seconds. The ary needle
voltage was 2.5 kV for positive tion mode and 2.9 kV for negative ionization
mode. The cone voltage was 20 V for both positive and negative ionization modes.
Leucine-Enkephaline was the standard nce used for the lock mass calibration.
Method 4:
In addition to the general procedure Bl: Reversed phase HPLC was carried out on an
Eclipse Plus-C18 column (3.5 um, 21 X 30 mm) from Agilent, with a flow rate of
1.0 ml/min, at 60°C. The gradient conditions used are: 95 % A (6.5 mM NH4AcO in
N 95/5), 5 % B (ACN), kept 0.2 minutes, to 100 % B in 3.0 minutes, kept to
3. 15 minutes and equilibrated to initial conditions at 3.3 s until 5.0 minutes.
Injection volume 2 ul.
Method 5.'
In addition to the general procedure B2: Reversed phase HPLC was d out on an
Eclipse Plus-C18 column (3.5 um, 21 X 30 mm) from Agilent, with a flow rate of
1.0 ml/min, at 60°C. The gradient conditions used are: 95 % A (6.5 mM NH4AcO in
HgO/ACN 95/5), 5 % B (ACN/ MeOH l/l), to 100 % B in 5.0 minutes, kept to 5. 15
minutes and equilibrated to initial conditions at 5.30 minutes until 7.0 minutes.
Injection volume 2 ul.
Method 6:
In addition to the general procedure B3: Reversed phase HPLC was carried out on a
e Plus-C18 column (3.5 um, 21 X 30 mm) from Agilent, with a flow rate of
1.0 ml/min, at 60°C. The gradient conditions used are: 95 % A (6.5 mM NH4AcO in
HZO/ACN 95/5), 5 % B (ACN), kept 0.2 minutes, to 100 % B in 3.0 minutes, kept to
3.15 minutes and equilibrated to initial conditions at 3.3 minutes until 5.0 minutes.
Injection volume 2 ul.
_ 72 _
General procedure C
The HPLC ement was performed using an Agilent 1100 module
sing a pump, a diode-array detector (DAD) (wavelength used 220 nm), a column
heater and a column as specified in the tive s below. Flow from the
column was split to a Agilent MSD Series G1946C and G1956A. MS detector was
configured with API-ES (atmospheric pressure electrospray ionization). Mass spectra
were acquired by ng from 100 to 1000. The capillary needle voltage was 2500 V
for positive tion mode and 3000 V for negative ionization mode. Fragmentation
e was 50 V. Drying gas temperature was maintained at 350 0C at a flow of 10
l/min.
Method 7:
In addition to general procedure C: Reversed phase HPLC was carried out on an YMC-
Pack ODS-AQ, 50x20 mm 5um column with a flow rate of 0.8 ml/min. Two mobile
phases (mobile phase A: H20 with 0.1 % TFA, mobile phase B: ACNwith 0.05 %
TFA) were used. First, 100 % A was hold for 1 minute. Then a gradient was applied to
40 % A and 60 % B in 4 minutes and hold for 2.5 minutes. Typical injection volumes
of 2 ul were used. Oven temperature was 50 oC. (MS polarity: positive).
Method 8:
In addition to general procedure C: Reversed phase HPLC was d out on an
te XB-C18, 50x21 mm 5um column with a flow rate of 0.8 ml/min. Two mobile
phases (mobile phase C: 10 mmol/L NH4HC03, mobile phase D:ACN) were used.
First, 100 % C was hold for 1 minute. Then a gradient was applied to 40 % C and 60 %
D in 4 minutes and hold for 2.5 minutes. Typical injection volumes of 2 ul were used.
Oven temperature was 50 oC. (MS polarity: positive).
General procedure D
The UHPLC measurement was performed using a Shimadzu 2010 LCMS-
system comprising a pump, photo diode array detector or (PDA) (wavelength
used 220 nm), a column oven and a column as specified in the respective methods
below. Flow from the column was split to a Shimadzu 2010 MSD or. MS
detector was configured with API-ES (atmospheric pressure electrospray ionization).
Mass spectra were acquired by scanning from 100 to 1000. The interface voltage was
4500 V for positive ionization mode. The nebulizing gas flow was 1.5 l/min. The CDL
(Curved Desolvation Line with heated capillary) temperature was 250 oC and the CDL
voltage was 30 V. The heat block temperature was 200 oC. The detector voltage was
3 5 1500 V.
_ 73 _
Method 9
In addition to general procedure D: Reversed phase UHPLC was carried out on a
e C18 (30>< 2.1mm 3.0um) column with a flow rate of 1.2 mL/min. Two mobile
phases (A: H20 with 0.15% TFA, B: ACN with 0.75% TFA) were used. First, 100 % A
was hold for 1 min. Then a gradient was applied to 40 % A and 60 % B in 0.9 min, kept
to 1.5 min and equilibrated to initial conditions at 1.51 min until 2.0 min. Typical
injection volumes of 1.0 uL were used. Oven temperature was 50 oC. (MS polarity:
positive).
General procedure E
The LC measurement was performed using a UPLC (Ultra Performance Liquid
Chromatography) Acquity (Waters) system comprising a binary pump with degasser,
an mpler, a diode-array detector (DAD) and a column as specified in the
respective methods below, the column is held at a temperature of 40°C. Flow from the
column was brought to a MS or. The MS detector was configured with an
electrospray tion source. Mass a were acquired on a triple quadrupole mass
spectrometer Quattro detector (Waters) by scanning from 100 to 1000 in 0.2 seconds
using an inter-scan delay of 0.1 seconds. The capillary needle voltage was 3 kV and the
source temperature was maintained at 130 oC. Cone voltage was 20V for ve and
ve ionization mode. Nitrogen was used as the zer gas. Data acquisition was
performed with nX-OpenlynX software (Waters).
Method 10:
In addition to the general procedure E: Reversed phase UPLC was carried out on a
Waters Acquity BEH (bridged ethylsiloxane/silica hybrid) Phenyl-Hexyl column (1.7
pm, 2.1 X 100 mm) with a flow rate of 0.343 . Two mobile phases (mobile phase
A: 95 % 7 mM7 mM NH4AcO / 5 % ACN, mobile phase B: 100 %ACN) were
employed to run a gradient condition from 84.2 % A and 15.8 % B (hold for
0.49 minutes) to 10.5 % A and 89.5 % B in 2.18 minutes, hold for 1.94 min and back to
the l conditions in 0.73 min, hold for 0.73 minutes. An injection volume of 2 ml
was used.
Melting Points
Values are either peak values or melt ranges, and are obtained with
experimental uncertainties that are commonly associated with this analytical method.
Mettler FP 81HT/FP90 — FP62 apparatus (indicated by FP90 and FP62 in Table 2)
For a number of compounds, melting points were determined in open capillary tubes
either on a Mettler FP62 or a Mettler FPS lHT/FP90 apparatus. Melting points were
_ 74 _
measured with a temperature gradient of 1, 3, 5 or 10°C/minute. Maximum temperature
was 300 oC. The melting point was read from a digital display.
Table 2: Analytical data — Rt means ion time (in min), [M+H]+ means the
protonated mass of the compound, method refers to the method used for (LC)MS.
[M+H]+ Method Melting Point
1 1.55 338 3 n.d.
2 1.6 381 3 n.d.
3 1.58 415 3 94.4 °C (FP62)
4 2.25 415 10 212.2 °C (FP62)
2.25 415 10 186.3 °C (FP62)
6 1.18 372 3 221.6 °C (FP62)
7 1.98 372 10 281.8 °C (FP62)
8 1.99 372 10 248.8 °C (FP62)
9 1.98 450 3 147.4 °C (FP62)
3.60 483 5 >300 °C (FP90)
11 2.90 483 10 147.8 °C (FP62)
12 2.90 483 10 221.8 °C (FP62)
13 0.97 414 2 99.4 °C (FP90)
14 1.74 433 3 n.d.
2.37 433 10 >300 °C (FP90)
16 2.37 433 10 >300 °C (FP90)
17 1.90 432 3 263.4 °C (FP90)
18 2.45 432 10 248 °C (FP90)
19 2.45 432 10 279.9 °C (FP90)
1.94 419 3 236.9 °C (FP90)
21 2.48 419 10 n.d.
22 2.49 419 10 220.4 °C (FP90)
23 2.26 421 3 276.3 °C (FP90)
24 2.29 408 3 186.4 °C (FP90)
2.23 433 3 180 °C (FP90)
26 2.18 446 3 n.d.
27 2.14 428 3 n.d.
_ 75 _
o. R [M+H] Method Melting P01nt
28 2.18 429 3 n.d.
29 2.25 415 3 >300 °C (FP90)
3 .31 446 5 n.d.
31 2.72 446 10 220.9 °C (FP62)
32 2.72 446 10 220 °C (FP62)
33 0.99 401 2 186 °C (FP90)
34 1.47 387 3 187 °C (FP62)
3.24 455 5 87.2 °C (FP62)
36 2.75 401 5 109.8 °C (FP62)
37 2.24 430 3 108.8 °C (FP90)
38 2.32 417 3 >300 °C (FP90)
39 2.53 449 3 n.d.
40 2.04 454 3 n.d.
41 2.18 415 3 n.d.
42 1.94 436 3 n.d.
43 1.86 394 3 n.d.
n.d. means not determined
SFCMS-Methods
General procedure A for SFC—MS methods
The SFC measurement was performed using an Analytical SFC system from
Berger Instruments (Newark, DE, USA) comprising a dual pump control module
(FCM-1200) for delivery of carbon dioxide (C02) and modifier, a thermal control
module for column heating (TCM2100) with temperature control in the range 1-150 OC
and column selection valves (Valco, VICI, Houston, TX, USA) for six different
columns. The photodiode array detector (Agilent 1100, Waldbronn, Germany) is
equipped with a high-pressure flow cell (up to 400 bar) and ured with a CTC LC
Mini PAL auto r (Leap Technologies, Carrboro, NC, USA). A ZQ mass
spectrometer (Waters, d, MA, USA) with an orthogonal Z-electrospray interface
is d with the stem. Instrument control, data collection and processing
were performed with an integrated platform consisting of the SFC ProNTo software
and MasslynX software.
Method 1
In addition to the general ure A: The chiral separation in SFC was carried out on
a CHIRALPAK AD-H column (4.6 mm X 500 mm) at 50 °C with a flow rate of3.0
ml/min. The mobile phase is CO2, 20% MeOH (containing 0.2% iPrNH2) hold 15.00
min, isocratic mode.
General procedure B
The SFC measurement was performed using an Analytical SFC system from
Berger instruments (Newark, DE, USA) comprising a FCM-1200 dual pump fluid
control module for delivering carbon dioxide (CO2) and modifier, a CTC Analytics
automatic liquid r, a TCM-20000 thermal control module for column heating
from room temperature to 80°C. An Agilent 1100 UV photodiode array detector
ed with a high-pressure flow cell ng up to 400 bars was used. Flow from
the column was split to a MS spectrometer. The MS detector was configured with an
atmospheric pressure ionization source. The following ionization parameters for the
Waters ZQ mass spectrophotometer are: corona: 9ua, source temp: 140°C, cone: 30 V,
probe temp 450°C, extractor 3 V, desolvatation gas 400L/hr, cone gas 70 L/hr.
Nitrogen was used as the nebulizer gas. Data acquisition was performed with a Waters-
Micromass MassLynX-OpenlynX data system.
Method 2
In addition to the general procedure B: The chiral separation in SFC was carried out on
a CHIRALPAK AD DAICEL column (10 um, 4.6 X 250 mm) at 35 °C with a flow rate
of 3.0 ml/min. The mobile phase is CO2, 60% Ethanol, 40% EtOH (containing 0.3%
iPrNH2) hold 7 min.
Table 3: Analytical SFC data — Rt means retention time (in min), [M+H]+ means the
protonated mass of the compound, method refers to the method used for SFC/MS
analysis of enantiomerically pure compounds.
Isomer
Co. No. [M+H]+ UV Area% Method n
Order"
Intermediate
A6(S)
Intermediate
6.88 230 100 1 B -
A6(R)
4 3.17 415 100 2 A -
4.17 415 100 2 B -
7 1.92 372 100 2 A -
_ 77 _
Isomer
Order"
3.05 2 B
11 4.95 483 100 3 B -
12 4.01 483 100 3 A -
4.14 433 100 4 A -
16 5.17 433 100 4 B -
18 3.07 432 100 5 A -
19 4.15 432 100 5 B -
21 2.81 419 100 3 A -
22 4.17 419 100 3 B -
27 4.37 433 89.33 6 A 79
28 4.97 446 70.11 7 A 40
31 3.33 446 100 3 A -
32 3.90 446 99.44 3 B -
39 5.20 449 91.51 6 A 83
40 3.40 454 93.61 7 A 88
>“A means the first isomer that elutes. B means the second isomer that elutes. The ee
was evaluated in the case of enantiomerically not pure nds.
Optical Rotations:
Optical rotations were measured on a Perkin-Elmer 341 polarimeter with a
sodium lamp and ed as follows: [ochtoc (c g/100 ml, solvent).
Table 4: Analytical data — Optical rotation values for enantiomerically pure
com I ounds
Wavelength Concentration Solvent Temp.
Co. No. OLD (0)
w/v% ° C
4 +20. 3 0 56
-3l.6 589 0.5 DMF 20
7 -70.7 589 0.45 DMF 20
8 +456 589 0.41 DMF 20
11 12.0 589 0.50 MeOH 20
12 -18.8 589 0.50 MeOH 20
2012/053455
_ 78 _
nm w/v% ° C
13 83.7 589 0.55 DVIF 20
18 136.8 589 0.51 DVIF 20
19 -l40.8 589 0.50 DVIF 20
21 -126.7 589 0.51 DVIF 20
22 115.2 589 0.54 DVIF 20
23 144.4 589 0.50 DVIF 20
24 111.4 589 0.51 DVIF 20
121.1 589 0.50 DVIF 20
29 111.0 589 0.51 DVIF 20
31 17.9 589 0.50 MeOH 20
32 -26.4 589 0.50 MeOH 20
33 56.6 589 0.65 DMF 20
81.5 589 0.50 DMF 20
37 29.2 589 0.52 DMF 20
38 14.8 589 0.49 DMF 20
41 65.2 589 0.50 DMF 20
42 77.1 589 0.50 DMF 20
n.d. means not determined
Pharmacological examples
The compounds provided in the present invention are inhibitors of the B-site
APP-cleaving enzyme 1 (BACEl). Inhibition of BACEl, an aspartic protease, is
ed to be relevant for treatment of Alzheimer’s Disease (AD). The production and
accumulation of B-amyloid peptides (AB) from the B-amyloid precursor protein (APP)
is believed to play a key role in the onset and progression of AD. AB is ed from
the amyloid precursor protein (APP) by sequential cleavage at the N— and C-termini of
the AB domain by etase and etase, respectively.
Compounds ofFormula (I) are expected to have their effect substantially at
BACEl by virtue of their ability to inhibit the enzymatic activity. The behaviour of
such inhibitors tested using a biochemical Fluorescence Resonance Energy Transfer
(FRET) based assay and a cellular dlisa assay in SKNBE2 cells described below and
which are le for the identification of such compounds, and more particularly the
compounds according to Formula (I), are shown in Table 3.
Biochemical FRET based assay
This assay is a Fluorescence Resonance Energy Transfer Assay (FRET) based
assay. The ate for this assay is an APP derived 13 amino acids peptide that
ns the ‘Swedish’ Lys-Met/Asn-Leu mutation of the amyloid precursor protein
(APP) B-secretase cleavage site. This substrate also ns two fluorophores:
(7-methoxycoumarinyl) acetic acid (Mca) is a fluorescent donor with excitation
wavelength at 320 nm and emission at 405 nm and 2,4-Dinitrophenyl (an) is a
proprietary quencher acceptor. The distance between those two groups has been
ed so that upon light excitation, the donor fluorescence energy is significantly
quenched by the acceptor, through resonance energy transfer. Upon cleavage by
BACEl, the hore Mca is separated from the quenching group an, ing the
full fluorescence yield of the donor. The increase in fluorescence is linearly related to
the rate of proteolysis (Koike H el al. J. Biochem. 1999, 126, 23 5-242).
Briefly in a 384-well format recombinant BACEl protein in a final concentration of
l ug/ml is incubated for 120 min at room temperature with 10 um substrate in
incubation buffer (40mM Citrate buffer pH 5.0, 0.04% PEG, 4% DMSO) in the
absence or ce of compound. Next the amount of proteolysis is directly measured
by fluorescence measurement at T=0 and T=l20 (excitation at 320 nm and on at
405 nm). Results are expressed in RFU, as difference between T120 and TO
A best-fit curve is fitted by a m sum of squares method to the plot of
%Controlmin versus compound concentration. From this an IC50 value (inhibitory
concentration causing 50% inhibition of activity) can be obtained.
LC = Median of the low control values
= Low control: Reaction without enzyme
HC = Median of the High control values
= High Control: Reaction with enzyme
%Effect = 100-[(sample-LC) / (HC-LC) >“100]
%Control = (sample /HC)* 100
%Controlmin = (sample-LC) / (HC-LC) >“100
The following exemplified compounds were tested essentially as described above and
exhibited the ing the activity:
Table 5
Biochemical FRET based assay
Co. No.
IIC50
1 6.28
2 7.08
WO 17027
_ 80 _
IC50
3 7.33
4 4.67
7.43
6 7.25
7 7.75
8 4.86
9 5.1
7.2
11 7.55
12 5.06
13 7.14
14 7.45
7.73
16 5.98
17 7.24
18 7.65
19 5.01
7.18
21 <4.52
22 7.59
23 7.4
24 7.49
7.56
26 7.31
27 7.22
28 7.16
29 7.09
6.77
31 4.97
32 7.20
33 7.19
_ 8] _
IC50
34 7.23
6.91
36 7.04
37 5.86
38 6.03
39 7.39
40 7.28
41 6.93
42 7.12
43 7.53
Cellular alisa assay in SKNBE2 cells
In two dlisa assays the levels of ABtotal and A1342 produced and secreted into
the medium of human neuroblastoma SKNBE2 cells are quantified. The assay is based
on the human neuroblastoma SKNBE2 expressing the wild type Amyloid Precursor
Protein (hAPP695). The compounds are d and added to these cells, incubated for
18 hours and then ements of A1342 and A13total are taken. A13total and A1342 are
measured by sandwich alisa. dlisa is a sandwich assay using biotinylated antibody
AbN/25 attached to streptavidin coated beads and antibody Ab4G8 or cAb42/26
conjugated acceptor beads for the detection of A13total and A1342 tively. In the
presence of A13total or A1342, the beads come into close proximity. The excitation of the
Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of
energy transfer in the Acceptor beads, resulting in light emission. Light emission is
measured after 1 hour tion (excitation at 650nm and emission at 615nm).
A best-fit curve is fitted by a minimum sum of squares method to the plot of
%Controlmin versus compound concentration. From this an IC50 value (inhibitory
concentration causing 50% inhibition of activity) can be obtained.
LC = Median of the low l values
= Low l: cells preincubated without compound, without biotinylated Ab in
the alisa
HC = Median of the High control values
= High Control: cells preincubated without nd
t = 100-[(sample-LC) / (HC-LC) >“100]
%Control = (sample /HC)* 100
_ 82 _
olmin = (sample-LC) / (HC-LC) >“100
The following exemplified compounds were tested essentially as described above and
exhibited the following the activity:
Table 6
Cellular alisa assay in Cellular alisa assay in
SKNBE2 cells SKNBE2 cells
Co. No.
Afitotal
IC50
21 <5 <5
22 7.17 7.21
23 8.75 8.71
24 8.48 8.41
8.88 8.87
_ 83 _
ar alisa assay in Cellular alisa assay in
SKNBEZ cells SKNBEZ cells
Afitotal
n.t. means not tested
tration ofin vivo eflicacy
AB peptide lowering agents of the invention can be used to treat AD in
mammals such as humans or alternatively demonstrating y in animal models
such as, but not limited to, the mouse, rat, or guinea pig. The mammal may not be
diagnosed with AD, or may not have a c predisposition for AD, but may be
transgenic such that it overproduces and eventually deposits AB in a manner similar to
that seen in humans afflicted with AD.
AB peptide lowering agents can be administered in any standard form using any
standard method. For example, but not limited to, AB peptide lowering agents can be in
the form of liquid, tablets or capsules that are taken orally or by injection. AB peptide
lowering agents can be administered at any dose that is sufficient to significantly
WO 17027 2012/053455
reduce levels of AB es in the blood, blood plasma, serum, cerebrospinal fluid
(CSF), or brain.
To determine whether acute administration of an AB42 peptide lowering agent
would reduce AB peptide levels in vivo, non-transgenic rodents, e. g. mice or rats were
used. s treated with the AB peptide lowering agent were examined and
compared to those untreated or treated with vehicle and brain levels of soluble AB42
and total AB were quantitated by standard techniques, for example, using ELISA.
ent periods varied from hours (h) to days and were adjusted based on the results
of the AB42 ng once a time course of onset of effect could be established.
A typical protocol for measuring AB42 lowering in vivo is shown but it is only
one of many variations that could be used to optimize the levels of detectable AB. For
example, AB e ng compounds were formulated in 20 % hydroxypropyl B
cyclodextrin. The AB peptide ng agents were administered as a single oral dose
(p.o.) or a single subcutaneous dose (s.c.) to overnight fasted animals. After a certain
time, usually 2 or 4 h (as indicated in Table 7), the animals were sacrificed and AB42
levels were analysed.
Blood was collected by decapitation and exsanguinations in reated
tion tubes. Blood was centrifuged at 1900 g for 10 minutes (min) at 4 OC and the
plasma recovered and flash frozen for later analysis. The brain was removed from the
cranium and hindbrain. The cerebellum was removed and the left and right hemisphere
were separated. The left hemisphere was stored at -18 0C for quantitative analysis of
test compound levels. The right hemisphere was rinsed with phosphate-buffered saline
(PB S) buffer and immediately frozen on dry ice and stored at -80 0C until
homogenization for biochemical assays.
Mouse brains from non-transgenic animals were resuspended in 8 volumes
of 0.4 % DEA (diethylamine) /50 mM NaCl containing protease inhibitors (Roche-
11873580001 or 59001) per gram oftissue, e.g. for 0.158 g brain, add 1.264 ml
of 0.4 % DEA. All samples were homogenized in the FastPrep-24 system (MP
Biomedicals) using lysing matrix D (MPBio #6913-100) at 6m/s for 20 seconds.
Homogenates were centrifuged at 221.300 x g for 50 min. The resulting high speed
supematants were then transferred to fresh eppendorf tubes. Nine parts of supernatant
were neutralized with 1 part 0.5 M Tris-HCl pH 6.8 and used to quantify ABtotal and
A842.
To quantify the amount of ABtotal and A842 in the soluble fraction of the brain
homogenates, Enzyme-Linked-Immunosorbent-Assays were used . Briefly, the
standards (a dilution of synthetic AB1-40 and AB1-42, Bachem) were ed in 1.5
ml Eppendorf tube in Ultraculture, with final concentrations ranging from 10000 to
0.3 pg/ml. The samples and standards were co-incubated with HRPO-labelled
N—terminal antibody for A1342 detection and with the biotinylated mid-domain antibody
4G8 for A13total ion. 50 ul of conjugate/sample or conjugate/standards mixtures
were then added to the antibody-coated plate (the capture antibodies selectively
recognize the C-terminal end of A1342, antibody JRF/cA1342/26, for A1342 detection and
the N—terminus of A13, antibody JRF/rA13/2, for A13total detection). The plate was
allowed to incubate overnight at 4 0C in order to allow ion of the antibody-
amyloid complex. Following this incubation and subsequent wash steps the ELISA for
A1342 quantification was finished by addition of Quanta Blu fiuorogenic peroxidase
substrate according to the manufacturer’s instructions (Pierce Corp, Rockford, 11). A
reading was performed after 10 to 15 min (excitation 320 nm /emission 420 nm).
For A13total detection, a Streptavidine-Peroxidase-Conjugate was added,
followed 60 min later by an addional wash step and addition of Quanta Blu fiuorogenic
peroxidase substrate according to the cturer’s ctions (Pierce Corp,
Rockford, 11). A reading was med after 10 to 15 min (excitation 320 nm
/emission 420 nm).
In this model at least 20 % A1342 lowering compared to untreated animals
would be advantageous.
The following ified nds were tested essentially as described above and
exhibited the following the activity:
Table 7:
A1342 ABtotal Route of Time after
(%Ctrl)_Mea (%Ctrl)_Mea administration administration
1—: 1—:
_ 86 _
AB42 ABtotal Route of Time after
(%Ctrl)_Mea (%Ctrl)_Mea administration administration
n.t. means not ; s.c. means subcutaneous ; p.o. means oral
Claims (12)
1. A compound of Formula (I) R1 N H2N N X4 L X1 X3 5 X2 or a er or a stereoisomeric form thereof, wherein R1 and R2 are independently selected from the group consisting of hydrogen, halo, cyano, C1-3alkyl, mono- and polyhalo-C1-3alkyl or C3-6cycloalkyl; R3 is selected from the group consisting of hydrogen, C1-3alkyl, 10 C3-6cycloalkyl, mono- and lo-C1-3alkyl, homoaryl and heteroaryl; X1, X2, X3, X4 are independently C(R4) or N, ed that no more than two thereof represent N; each R4 is selected from the group consisting of hydrogen, halo, C1-3alkyl, mono- and polyhalo-C1-3alkyl, cyano, C1-3alkyloxy, mono- and polyhalo-C1-3alkyloxy; 15 L is a bond or -N(R5)CO-, wherein R5 is hydrogen or C1-3alkyl; Ar is homoaryl or heteroaryl; wherein homoaryl is phenyl or phenyl tuted with one, two or three substituents selected from the group consisting of halo, cyano, C1-3alkyl, C1-3alkyloxy, mono- and polyhalo-C1-3alkyl, mono- and polyhalo-C1-3alkyloxy; 20 aryl is selected from the group consisting of pyridyl, pyrimidyl, pyrazyl, pyridazyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, thiadiazolyl, oxazolyl, and oxadiazolyl, each optionally substituted with one, two or three tuents selected from the group consisting of halo, cyano, C1-3alkyl, kyloxy, mono- and polyhalo-C1-3alkyl, mono- and polyhalo-C1-3alkyloxy; or 25 an addition salt or a solvate thereof.
2. The compound of claim 1 wherein, R1 and R2 are ndently selected from hydrogen and C1-3alkyl; X1, X2, X3, X4 are independently C(R4) wherein each R4 is selected from en and halo; L is a bond or -N(R5)CO-, wherein R5 is hydrogen; Ar is homoaryl or aryl; 5 wherein homoaryl is phenyl or phenyl substituted with one or two substituents selected from the group consisting of halo, cyano, C 1-3alkyl, C1-3alkyloxy, and polyhalo-C1-3alkyloxy; heteroaryl is selected from the group consisting of pyridyl, pyrimidyl, and pyrazyl, each optionally substituted with one or two substituents selected from the group 10 consisting of halo, cyano, C1-3alkyl, C1-3alkyloxy, and lo-C1-3alkyloxy; or an addition salt or a solvate thereof.
3. The compound of claim 1 wherein, R1 and R2 are hydrogen; 15 X1, X2, X3, X4 are CH; L is a bond or -N(R5)CO-, wherein R5 is en; Ar is homoaryl or heteroaryl; wherein homoaryl is phenyl substituted with chloro; heteroaryl is selected from the group consisting of pyridyl and pyrimidyl, each 20 optionally substituted with one or two substituents selected from the group consisting of chloro, fluoro, cyano, methyl, and y; or an addition salt or a solvate thereof.
4. The compound of claim 1 wherein the carbon atom substituted with R3 has the 25 R-configuration.
5. A pharmaceutical ition comprising a therapeutically effective amount of a compound as defined in any one of claims 1 to 4 and a ceutically acceptable r.
6. A process for preparing a pharmaceutical composition as defined in claim 5, wherein a pharmaceutically acceptable carrier is intimately mixed with a therapeutic ally effective amount of a compound as defined in any one of claims 1 to 4.
7. A compound as defined in any one of claims 1 to 4 for use in the treatment, prevention or prophylaxis of Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy , Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia 5 associated with beta-amyloid.
8. Use of a compound as defined in any one of claims 1 to 4 or a pharmaceutical composition as defined in claim 5 in the manufacture of a medicament for treating a disorder selected from the group ting of Alzheimer's disease, mild 10 cognitive impairment, senility, ia, dementia with Lewy bodies, Down's syndrome, ia associated with stroke, dementia associated with Parkinson's disease and ia associated with beta-amyloid.
9. The compound of claim 1, ntially as herein described with reference to any 15 one of the es thereof.
10. The pharmaceutical composition of claim 5, wherein the compound is substantially as herein described with reference to any one of the Examples thereof. 20
11. The process of claim 6, wherein the nd is substantially as herein described with reference to any one of the Examples thereof.
12. The use of claim 8, substantially as herein described with reference to any one of the Examples thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11156463.9 | 2011-03-01 | ||
EP11156463 | 2011-03-01 | ||
PCT/EP2012/053455 WO2012117027A1 (en) | 2011-03-01 | 2012-02-29 | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace) |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ614551A NZ614551A (en) | 2014-06-27 |
NZ614551B2 true NZ614551B2 (en) | 2014-09-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2824360C (en) | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace) | |
EP2683721B1 (en) | 3,4-DIHYDRO-PYRROLO[1,2-a]PYRAZIN-1-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | |
CA2807904C (en) | 4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta-secretase (bace) | |
CA2819175C (en) | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (bace) | |
NZ614551B2 (en) | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace) | |
NZ615720B2 (en) | 3,4-DIHYDRO-PYRROLO[1,2-a]PYRAZIN-1-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | |
NZ626662A (en) | 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives |